1 Title: Identification of a serum proteomic biomarker panel using diagnosis specific ensemble learning and symptoms for early 2 3

pancreatic cancer detection

4

#### 5 **Authors:**

- Alexander Ney<sup>1,\*</sup>, Nuno R. Nené<sup>2,3,4\*</sup>, Eva Sedlak<sup>2</sup>, Pilar Acedo<sup>1</sup>, Oleg Blyuss<sup>2,5,6</sup>, 6
- Harry J. Whitwell<sup>2,7,8</sup>, Eithne Costello<sup>9</sup>, Aleksandra Gentry-Maharaj<sup>2,10</sup>, Norman R. 7
- Williams<sup>11</sup>, Usha Menon<sup>10</sup>, Giuseppe K. Fusai<sup>12</sup>, Alexey Zaikin<sup>2,13,14</sup>, Stephen P. 8
- Pereira<sup>1,\*</sup>. 9

10 11

### Affiliations:

12

13 <sup>1</sup> Institute for Liver and Digestive Health, University College London, Upper 3<sup>rd</sup> Floor, Royal Free Campus, Rowland Hill Street, London NW3 2PF, United Kingdom 14

15

<sup>2</sup> Department of Women's Cancer, EGA Institute for Women's Health, University 16 17 College London, 84-86 Chenies Mews, London, WC1E 6HU, United Kingdom

18

19 <sup>3</sup> Cancer Institute, University College London, 72 Huntley St, London, WC1E 6DD, 20 United Kingdom.

21

22 of Statistical University College Department Science. London 23 1-19 Torrington Place, London, WC1E 6BT, United Kingdom

24

<sup>5</sup> Wolfson Institute of Population Health, Queen Mary University of London, 25 Charterhouse Square, EC1M 6BQ, London, United Kingdom 26

27

- <sup>6</sup> Department of Pediatrics and Pediatric Infectious Diseases, Institute of Child's 28 29 Health, Sechenov First Moscow State Medical University (Sechenov University),
- 30 Moscow, Russia
- <sup>7</sup> National Phenome Centre and Imperial Clinical Phenotyping Centre, Department of 31
- Metabolism, Digestion and Reproduction, IRDB, Building Imperial College London, 32
- W12 ONN, United Kingdom 33
- <sup>8</sup> Section of Bioanalytical Chemistry, Division of Systems Medicine, Department of 34
- 35 Metabolism, Digestion and Reproduction, Sir Alexander Fleming Building, Imperial
- 36 College London, SW7 2AZ, United Kingdom

37

38 Department of Molecular and Clinical Cancer Medicine, University of 39 Liverpool, Liverpool, United Kingdom

40

- <sup>10</sup> MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, 41
- University College London, 90 High Holborn, 2nd Floor, London, WC1V 6LJ, United 42
- 43 Kingdom

45 46	Division of Surgery & Interventional Science, University College London, London, United Kingdom
47 48 49 50	<sup>12</sup> HPB & Liver Transplant Unit, Royal Free London, London NW3 2QG, United Kingdom
51 52 53	<sup>13</sup> Institute for Cognitive Neuroscience, University Higher School of Economics, Moscow, Russia
54 55 56	<sup>14</sup> Department of Mathematics, University College London, London WC1H 0AY, United Kingdom
57 58	* These authors contributed equally to the work
59	To whom correspondence should be addressed:
60	Dr Alexander Ney (Email: <u>alexander.ney.15@ucl.ac.uk</u> )
61	Dr Nuno Rocha Nené (Email: <u>nuno.nene.10@ucl.ac.uk</u> )
62 63 64	Prof Stephen Pereira (Email: <u>stephen.pereira@ucl.ac.uk</u> )
65	Abstract
66 67	BACKGROUND: The grim (<10% 5-year) survival rates for pancreatic ductal adenocarcinoma (PDAC)
68	are attributed to its complex intrinsic biology and most often late-stage detection. The overlap of
69	symptoms with benign gastrointestinal conditions in early stage further complicates timely detection.
70	The suboptimal diagnostic performance of carbohydrate antigen (CA) 19-9 and elevation in benign
71	hyperbilirubinaemia undermine its reliability, leaving a notable absence of accurate diagnostic
72	biomarkers. Using a selected patient cohort with benign pancreatic and biliary tract conditions we aimed
73	to develop a biomarker signature capable of distinguishing patients with non-specific yet concerning
74	clinical presentations, from those with PDAC.
75	
76	METHODS: 539 patient serum samples collected under the Accelerated Diagnosis of neuro Endocrine
77	and Pancreatic TumourS (ADEPTS) study (benign disease controls and PDACs) and the UK
78	Collaborative Trial of Ovarian Cancer Screening (UKCTOCS, healthy controls) were screened using
79	the Olink Oncology II panel, supplemented with five in-house markers. 16 specialized base-learner

classifiers were stacked to select and enhance biomarker performances and robustness in blinded samples. Each base-learner was constructed through cross-validation and recursive feature elimination in a discovery set comprising approximately two thirds of the ADEPTS and UKCTOCS samples and contrasted specific diagnosis with PDAC.

RESULTS: The signature which was developed using diagnosis-specific ensemble learning demonstrated predictive capabilities outperforming CA19-9 and individual biomarkers in both discovery and validation sets. An AUC of 0.98 (95% CI 0.98 – 0.99) and sensitivity of 0.99 (95% CI 0.98 - 1) at 90% specificity was achieved with the ensemble method, which was significantly larger than the AUC of 0.79 (95% CI 0.66 - 0.91) and sensitivity 0.67 (95% CI 0.50 - 0.83), also at 90% specificity, for CA19-9, in the discovery set (p=0.0016 and p=0.00050, respectively). During ensemble signature validation, an AUC of 0.95 (95% CI 0.91 – 0.99), sensitivity 0.86 (95% CI 0.68 - 1), was attained compared to an AUC of 0.80 (95% CI 0.66 – 0.93), sensitivity 0.65 (95% CI 0.48 – 0.56) at 90% specificity for CA19-9 alone (p=0.0082 and p=0.024, respectively). When validated only on the benign disease controls and PDACs collected from ADEPTS, the diagnostic-specific signature achieved an AUC of 0.96 (95% CI 0.92 – 0.99), sensitivity 0.82 (95% CI 0.64 – 0.95) at 90% specificity, which was still significantly higher than the performance for CA19-9 taken as a single predictor, AUC of 0.79 (95% CI 0.64-0.93) and sensitivity of 0.18 (95% CI 0.03 – 0.69) (p= 0.013 and p=0.0055, respectively).

CONCLUSION: Our ensemble modelling technique outperformed CA19-9, individual biomarkers and prevailing algorithms in distinguishing patients with non-specific but concerning symptoms from those with PDAC, with implications for improving its early detection in individuals at risk.

### Introduction

Pancreatic cancer (PC) remains lethal with approximately 500,000 new cases diagnosed globally each year with a comparable number of deaths. Pancreatic ductal adenocarcinoma (PDAC) ranks as the seventh primary cause of cancer-related mortality (1, 2). Projections suggest that by 2030, mortality rates from PDAC will exceed that of other prevalent cancers, a shift which is attributed to an increasing incidence of obesity, diabetes mellitus, alcohol consumption in some regions (Europe, North America,

and Oceania) and advancements in detection and institution of screening initiatives that facilitate the timely identification of more common cancers (1-3). Across the European Union and the United Kingdom, mortality rates of PDAC have surpassed lung, breast and prostate cancers, underscoring the pressing need for enhancements in strategies for both detection and treatment of PC (4). These improvements are crucial to mitigate the growing burden of this disease (5, 6).

The overall 5-year survival for PC patients is less than 10%. These figures improve in patients diagnosed with pre-invasive lesions (intraepithelial neoplasia, mucinous cystic lesions) or small tumours (< 2cm) detected at a localised stage (7). Patients with resectable disease are only identified in less than 20% of cases and advances in early detection strategies hold potential for improving these dismal figures (8, 9). The relatively low incidence and lifetime risk for PC in the general population (1.3%) preclude asymptomatic, average-risk adult (>50 age) screening, and efforts are rather focused on high-risk populations (9-11). Internationally, screening and surveillance is therefore recommended only in high-risk individuals (genetically predisposed, family history and high-risk pancreatic cysts), where a lifetime risk of at least 5% justifies their surveillance (9, 10, 12, 13). While surveillance in these high-risk cohorts is consensus, we also reported on symptomatic cohorts in which the increased risk could justify investigations, as an additional risk group (9, 14).

Existing evidence regarding the effect of timely diagnosis on outcomes in PDAC are limited, mostly due to the lack of randomisation, appropriate statistical considerations and homogenisations of study populations, and the topic remains an area of strong debate (15). Yet with research indicating that PDAC progresses from early (T1) stage to advanced (T4) in just over a year, and larger pancreatic cancers (>2 cm) metastases are detectable within approximately 3.5 months (range between 1.2 to 8.4 months), it is very likely that prompt identification of PC would improve its prognosis (15-17).

The reality of the situation however is that disease rarity, the presence of non-localising symptoms, the relatively low positive predictive values even for cancer specific 'red-flag' and advanced symptoms (e.g. weight loss, painless jaundice of 4-13%) challenge timely recognition in primary care settings, and a substantial number of PC patients are diagnosed following prolonged periods of clinical uncertainty (18, 19). Previous case-control primary care studies associated various abdominal symptoms and increased

frequency of primary care consultations with PDAC, over the two years preceding its diagnosis (14, 20, 21). These data suggest another potential window of opportunity for acceleration of PC detection.

In roughly 30% of patients, PC manifests in the form of jaundice indicating tumour induced biliary obstruction, which is more evident in pancreatic head tumours (22). Together with significant weight loss, these frequently represent an already advanced disease. Although most often explained by benign aetiologies, symptoms such as back or epigastric pain, dyspepsia, anorexia, bloating, changes in consistency of stool, weight loss and anxiety/depression may also indicate an underlying pancreatic malignancy (14, 20-23). Such symptoms in adults (age > 60 years) with lifestyle factors (including heavy alcohol and tobacco consumption, obesity) and on the background of new or long-standing diabetes and chronic pancreatitis, are worrisome (9, 14, 21). In such patients, the United Kingdom National Institute for Health and Care Excellence (NICE) recommends direct access to cross-sectional imaging by CT, FDG-PET/CT, or EUS within two weeks (24). Although shorter diagnostic intervals are associated with extended survival, the non-specific clinical presentation and the complexity of diagnostic pathways result in delayed referral to specialised centres (14).

To accelerate and improve cancer detection rates in the UK, 'electronic cancer decision support tools' (eCDST) have been developed to support primary care clinicians in fast tracking investigations in cases of suspected cancer (25-27). Risk prediction models/algorithms such as QCancer (25-27) combine symptoms data, patient risk factors and laboratory tests to predict a risk of undiagnosed cancers of various anatomical sites (colon, pancreas, renal, gastro-oesophageal and ovarian). These are digitally available for primary care physicians through patient record and data management portals (such as EMIS Web and INPS) and where higher risk justifies further investigations, could be combined with blood biomarker panels for further risk stratification prior to more invasive workup.

When suspected, establishing a diagnosis will involve measurement of the serum marker CA19-9, cross-sectional (computed tomography or magnetic resonance) imaging and histopathology (endoscopic ultrasound guided tissue biopsy; EUS-FNB). CA19-9 is most reliable as a marker of tumour resectability, prognosis and monitoring of disease progression (28, 29), but as a diagnostic marker it performs poorly (median sensitivity and specificity of ~80%; AUC= 0.82), particularly in stage I/II disease

and in Lewis body negative patients (30, 31). The development of reliable and accurate diagnostic biomarkers is essential for risk stratification and prioritisation of further investigations, as well as justification of invasive interventions where the findings on imaging are unequivocal (32).

Using serum samples collected from a selected study cohort with benign pancreatic and biliary tract conditions and applying robust machine learning stacked modelling, we therefore developed a serum biomarker signature capable of differentiating PC patients from healthy individuals and patients with benign abdominal conditions presenting with non-specific yet concerning symptoms for pancreatic cancer, at higher rates than CA19-9 and other state-of-the-art biomarkers.

### **Materials and Methods**

### **Study Design**

As our cohort, we used serum samples from the Accelerated Diagnosis of neuro Endocrine and Pancreatic TumourS (ADEPTS) study (33) (UCL/UCLH Research Ethics Committee reference 06/Q0512/106, IRAS Number 234637, NIHR portfolio no. 7343) study - an early detection study aimed at detecting pancreatic cancer in patients at an earlier stage. As part of the Early Diagnosis Research Alliance (EDRA), the ADEPTS study (previously referred to as TRANSlational research in BILiary tract and pancreatic diseases (*TRANSBIL*) study), commenced in 2018 and included a multicentre prospective blood sample collection from patients with non-specific but concerning symptoms associated with PDAC. Patients were recruited at gastroenterology/hepatobiliary and surgical clinics at University College London (UCLH) and the Royal Free Hospitals (RFH), London, UK. Blood samples were collected from subjects with benign hepatobiliary conditions as well as those with PDAC (stages I-IV). All patients recruited to the ADEPTS study provided written informed consent.

For PDAC patients, tumour staging was performed according to the AJCC 8<sup>th</sup> edition (TNM) based on cross-sectional imaging and for those undergoing surgery, based on multi-disciplinary team recordings.

All included PDAC cases were histologically confirmed by UCLH and RFH local pathologists based on

tissue analysis obtained by endoscopic ultrasound guided fine needle biopsies or specimens obtained during surgical resection.

For benign disease controls, patients were selected to include the following diagnoses: chronic pancreatitis, intraductal papillary mucinous neoplasms (IPMN), or benign pancreatic diseases (e.g., serous cystadenomas and pancreatic heterotopia). Patients with acute and chronic pancreatitis, pancreatic cysts, benign biliary duct diseases (e.g., IgG4 disease), liver disease, gastritis/reflux disease, gallstones as well as those with familial history of pancreatic cancer, were also used. Samples also included those collected from patients presenting with non-specific symptoms which were not otherwise explained by an underlying gastrointestinal pathology (such as non-specific abdominal pain and irritable bowel syndrome) as well as other malignancies. Medical history and confirmation of diagnosis was obtained from hospital medical records and included GP and secondary clinic referral letters. For 45 patients, a QCancer score was available at time of specialist centre consultations. QCancer calculates the probability of an individual as harbouring an existing, yet undiagnosed cancer, by considering their specific risk factors and presenting symptoms. These are digitally available for primary care physicians through patient record and data management portals such as EMIS Web and INPS and designed as clinical decision support tools to aid in assessment of need for specialist referrals (34).

To further represent the healthy population we also used samples from 72 healthy control UKCTOCS (35) samples that were collected from a nested case control discovery study part of UKCTOCS reported before (36), which had been previously approved by the Joint UCL/UCLH Research Ethics Committee A (Ref. 05/Q0505/57). Written informed consent for the use of samples in the UKCTOCS trial and secondary ethically approved studies was obtained from donors and no data allowing identification of patients was provided. The original UKCTOCS dataset from which data was used here was derived from serum samples collected from post-menopausal women, aged between 50 and 74 years, who were recruited between the years 2001 and 2005 (35). The collection of these samples was conducted in accordance with a specific Standard Operating Procedure (SOP) (37, 38). For the current work our interest lies only with the UKCTOCS matched non-cancer controls, i.e., with no cancer registry code, from individual women selected based on collection date, age, and centre to minimize variation due to handling and storage. Comprehensive information regarding diabetes status for the selected UKCTOCS participants was either unavailable or incomplete. In addition, data on disease duration was

not accessible. Consequently, it was not feasible to stratify samples to discovery and validation sets based on the type of diabetes they may have had. For the purposes of this study, only healthy controls that were matched to PDAC cases, with less than one year to diagnosis, were utilized.

A total of 539 serum samples (493 controls and 46 PDAC cases, see Table 1) were analysed using the Olink multiplex immunoassay Oncology II panel in addition to five in-house markers: Carbohydrate antigen 19-9 (CA19-9), Interleukin 6 Cytokine Family Signal Transducer (IL6ST/IL6RB), von Willebrand factor (VWF), Pyruvate kinase isozymes M1/M2 (PKM/PKM2) and Thrombospondin 2 (THBS2/TSP2). The selection of additional markers, beyond CA19-9, was informed by our preceding research in early detection of PDAC (36, 39). In those studies, a panel of markers was identified due to its demonstrated ability to facilitate the early detection of pancreatic cancer, with a lead time of up to two years prior to diagnosis.

### Serum analyte measurements

All ADEPTS (33) samples were randomized for testing. Supplementary Table 1 summarizes dilution factors and coefficients of variation. CA19-9 was measured using the Mucin PC/CA19-9 ELISA Kit (Alpha Diagnostic International) according to the manufacturer, using a 1:4 serum dilution. For VWF, we resorted to the Von Willebrand Factor Human ELISA Kit (abcam) at a 1:100 serum dilution. IL6ST/IL6RB by Quantikine human soluble gp130 (R&D Systems), according to manufacturer recommendations, at a 1:100 serum dilution. THBS2/TSP2 was measured using the Quantikine Human Thrombospondin-2 Immunoassay (R&D Systems) at a 1:10 serum dilution. Pyruvate kinase M2 (PKM2) was measured with an ELISA (Cloud-Clone Corp) at a 1:10 dilution.

We outsourced tests using the multiplex immunoassay Oncology II panel from Olink on all samples. This Olink panel measured known cancer antigens, growth factors, receptors, angiogenic factors, and adhesion regulators (as detailed in Supplementary Table 2). Identical assays were performed on a subset of samples derived from the UKCTOCS study (37, 38).

To bridge the normalized protein expression values from Olink between the UKCTOCS and ADEPTs datasets, we selected a representative sample set of 16 from each cohort and plated them together.

Subsequently, a correction was applied to the datasets using the statistical algorithms recommended in the Olink data normalization white paper (40). This method ensured that the data from different batches and studies were comparable, thereby enhancing the robustness and validity of the findings.

261

258

259

260

### Statistical analysis

262263264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

The selected set of ADEPTS samples used in this work was partitioned into two distinct sets: a discovery subset, comprising two-thirds of the total sample size, and a validation subset, encompassing the remaining one-third. Allocation into each set was performed by stratifying for specific age ranges, diabetes status, PDAC status and control diagnosis class. For the PDAC cases, tumour stage was also used. The age stratification ranges were the following: 18<Age≤28; 29<Age≤38; 39<Age≤48; 49<Age≤58; 59<Age≤68; 69<Age≤78; Age≥79. The samples assigned to the control class were made of benign conditions such as: Sphincter of Oddi dysfunction, Pancreatic Cyst, Other Cancer, Other Biliary Duct Disease, No Relevant Diagnosis, Liver Disease, Irritable Bowel Syndrome, IgG4 Disease, Gastritis/Reflux Disease, Gallstone Disease, Familial Pancreatic Cancer, Chronic Pancreatitis, Acute Pancreatitis, Isolated LFT Derangement and Non-specific Abdominal Pain. We also added an additional set of healthy control samples collected from a nested study done in UKCTOCS samples used in a previous paper (41). The controls matched by age to the PDAC cases in the UKCTOCS cohort that had a time to diagnosis below up to one year were selected. The allocation of these controls to the discovery or validation sets was done according to the division used in our previous work (41). The number of controls and cases collected for this study can be visualized in Figure 1. UKCTOCS controls are identified as 'Healthy'. The discovery-validation split puts the prevalence of PDAC in the discovery set at close to 8%. The prevalence of PDAC in the resulting validation was approximately 14%.

281282

283

284

285

286

287

Receiver operating characteristic (ROC) curves were constructed for each model to assess diagnostic performance. The area under the curve (AUC) for the ROC curves was used as the metric. Models and techniques were compared based on their rank in the discovery under a 10-time repeated 5-fold cross-validation resampling strategy. ROC curves were generated with the *pROC* R package (version 1.18.0, <a href="https://cran.r-project.org/web/packages/pROC/index.html">https://cran.r-project.org/web/packages/pROC/index.html</a> ). 95% CI for AUCs were determined by stratified bootstrapping. All AUC confidence intervals crossing 0.5 were considered to be non-

significant. P values comparing ROC curves were also calculated using the *pROC* package, under a one-sided bootstrap approach with 10000 runs.

In order to evaluate the association between each of the single markers available for this work, including clinical covariates (see Table 1 and Figure 1), and PDAC status, we used a logistic regression model implemented in the *logistf* R package (<a href="https://cran.r-project.org/web/packages/logistf/index.html">https://cran.r-project.org/web/packages/logistf/index.html</a>, version 1.24.1). This approach fits a logistic regression model using Firth's bias reduction method. The reported confidence intervals for odds ratios and tests were based on the profile penalized log likelihood and incorporate the ability to perform tests where contingency tables are asymmetric or contain zeros. The performance of single marker models was also verified in the discovery and validation sets (see Supplementary Figure 1 and Supplementary Table 3 and 4). The same package was also used to verify the association of the presence of symptoms and PDAC status (see Figure 4).

A comprehensive multi-dimensional examination of the collated data was conducted by employing two distinct analytical frameworks. The first was a stacked ensemble algorithm where base-learners were developed according to the same algorithm but in subsets of the discovery set where samples belonging to a specific control diagnosis class were contrasted against the same 24 PDAC cases (see for example the proportions in Figure 1). The resulting base-learners were then stacked by a logistic regression model, (see Supplementary Table 5 for the resulting coefficients and Supplementary Figure 2 for the stacking procedures). This approach aimed to leverage the predictive power of multiple models, thereby enhancing the robustness and potentially leading to more precise predictive outcomes (36, 42, 43). For each base-learner classifier we resorted to a Recursive Feature Elimination (RFE) routine with logistic regression as the fitting algorithm available through caret (version 6.0-93, https://cran.rproject.org/web/packages/caret/index.html) and oversampling of the minority class. This secures robust selection of features when combined with cross validation and the selection process is encapsulated inside an outer layer of resampling (44-46). Due to the prevalence of PDAC cases in the whole dataset being low, random under sampling of the majority class, here benign and healthy controls, would not have been sufficient to meet the demands of most algorithms. Therefore, creating an ensemble of classifiers specialised in contrasting a specific diagnostic class against PDAC allowed us to create more balanced subsets leading to increased performance (Figure 2). For the samples collected from UKCTOCS no symptoms information was available and, therefore, we created a separate classifier associated with this subset of individuals.

In addition to the stacked approach we also fitted state-of-the-art algorithms such regularized random forests (RRF, version 1.9.4, <a href="https://cran.r-project.org/web/packages/RRF/index.html">https://cran.r-project.org/web/packages/RRF/index.html</a>); extreme gradient boosting trees (xgbTree, version 1.6.0.1, <a href="https://cran.r-project.org/web/packages/xgboost/index.html">https://cran.r-project.org/web/packages/xgboost/index.html</a>); and a generalized linear model with RFE applied to the whole discovery set (RFE glm, in *caret*). The latter allowed for testing if the division into diagnosis specific classifier ensembles was advantageous at low but representative prevalence (Figure 2) in a situation where we want to contrast PDAC cases with confounding diseases in a clinical setting. All base-models were trained by 10 times repeated 5-fold cross-validation with over-sampling of the minority class (see Table 1 and Supplementary Tables 6 and 7 for information on prevalence).

To verify if the PDAC index developed with the ensemble stacked approach had any association with metrics used in the clinic but not taken into account in any stage of algorithm training, we also gathered the QCancer score (47) for individuals in the ADEPTS study (see Figure 6).

The procedure for assessing feature importance in each base learner was a model-agnostic method based on a simple feature importance ranking measure (48), implemented in the R package *vip* (version 0.3.2, <a href="https://cran.r-project.org/web/packages/vip/index.html">https://cran.r-project.org/web/packages/vip/index.html</a>). The model-agnostic interpretability, by decoupling the interpretation from the model itself, introduces a level of flexibility that enables its application across any supervised learning algorithm. Despite the algorithm used for each diagnosis-specific classifier being the same, the model-agnostic approach allows us to be able to generalise the computed importances to other work in the literature.

Enrichment analysis for each of the signatures developed was performed with the *gprofiler2* R package (version 0.2.1, <a href="https://cran.r-project.org/web/packages/gprofiler2/index.html">https://cran.r-project.org/web/packages/gprofiler2/index.html</a> ). A threshold for multiple comparison correction under the framework of false discovery rate was instituted at 0.05.

### Results

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

### **Data set characteristics**

In the full set of samples collected from the ADEPTS cohort, age at the time of sample collection, 57.44 (range from 19.00 to 93.00) for controls and 69.72 (range from 43.00 to 91.00) for PDAC cases, emerged as a risk factor (OR= 1.06 (95% CI 1.04 - 1.09), p= $2.47 \times 10^{-7}$ ) (Table 1). As a predictor in a logistic regression model age as a feature achieved a ROC AUC of 0.73 (95% CI 0.66-0.79), with a cut-off at 61.5 years (calculated using the Youden J statistic). This finding was also observed in both the discovery (Supplementary Table 6 and Figure 1, ROC AUC 0.74 (95% CI 0.64-0.83), cut-off at 70) and validation sets (Supplementary Table 7 and Figure 1, 0.74 (95% Cl 0.64-0.82), cut-off at 60), which incorporated not only ADEPTS samples but also healthy control samples collected from UKCTOCS (35). In our past research which was focused exclusively on UKCTOCS longitudinal samples, age similarly emerged as a risk factor for PDAC (36). Furthermore, gender (OR=2.72 (95% CI 1.46 - 5.27), p=0.0015) and ethnicity taken as a one-hot encoded variable (OR=2.02 (95% CI 1.34 - 3.03), p= $6.56 \times 10^{-4}$ ) were also confirmed as significantly associated with an increased risk of PDAC (Table 1). In the whole set of samples collected from the ADEPTS cohort, men had a 2.72-fold risk of PDAC compared to their female counterparts. Individuals of Caucasian ethnicity demonstrated a decreased risk of PDAC in a one versus rest calculation (OR=0.38 (95% CI 0.20 - 0.69), p=0.0018) and no significant association was found between PDAC risk and Asian or Afro-Caribbean ethnicity in the ADEPTS dataset under the same modelling framework (Table 1). The association of gender and PDAC was also confirmed in the discovery (OR=4.98 (95% CI 2.08 - 13.50), p=0.00023, Supplementary Table 6 and Figure 1) and validation sets (OR=2.65 (95% CI 1.11 - 6.58), p=0.028 Supplementary Table 7 and Figure 1), but ethnicity, taken as a one-hot encoded variable, remained a significant predictor of PDAC only in the validation set (OR=2.66 (95% CI 1.42 – 5.17), p=0.0020) (Supplementary Table 7 and Figure 1), which as was highlighted above also includes healthy control UKCTOCS samples. Within the group of the clinical covariates only age and gender are significant predictors of PDAC in both the discovery and validation set (Figure 1), with only age achieving a significant AUC in the validation set between these two. However, this was concomitant with remarkably low sensitivity (Sens), positive predictive (PPV) value and negative predictive value (NPV) at 90% specificity (Spec): AUC 0.74 (95% CI 0.64-0.82), Sens 0.13 (95% CI 0 - 0.39), PPV 0.16 (95% CI 0 - 0.36), NPV 0.88 (95% CI 0.86 - 0.91).

### Development of PDAC biomarker signature in the presence of confounding conditions

To aid the early detection of this cancer in individuals at risk, we aimed to develop a biomarker signature that could be used to differentiate between suspected PDACs and benign biliary conditions that often overlap in clinical presentation. We applied a uniquely developed ensemble learning model, with a logistic regression stacking layer (see Supplementary Figure 2 and statistical analysis in the Methods section), to a set of 539 serum samples (493 controls and 46 PDAC cases) which were analysed using the Olink Oncology II panel as well as four additional biomarkers we previously reported on (36). These included IL6ST, VWF, THBS2 and CA19-9. The oncogenic and prognostic glycolytic enzyme PKM2 was additionally selected based on our past report of its diagnostic utility in biliary tract cancer patients (49-51).

The application of stacked ensemble modelling as presented herein bolsters the robustness of predictive outcomes, enhancing the performance of biomarker panels through the incorporation of serum biomarker levels and relevant clinical covariates for distinct diagnostic classes. Each component classifier within the ensemble is designed to provide a specialized distinction between confounding diagnoses and PDAC, thereby establishing a heterogeneous set of classifiers that facilitates the precise identification of PDAC (see statistical analysis section in Methods). Previous studies have attested to the beneficial role of ensemble methods in augmenting early detection of PDAC against only healthy controls (36). The implementation of stacked (Stack, Figure 2), specialized classifiers, developed within the discovery set, generated a biomarker signature capable of predicting PDAC with an AUC of 0.98 (95% CI 0.98 - 0.99), sensitivity of 0.99 (95% CI 0.98 - 1), PPV 0.92 (95% CI 0.91 - 0.92) and NPV 0.99 (95% CI 0.97 - 1) at 90% specificity. In contrast, the predictive efficacy of CA19-9 in the discovery set taken as a single predictor under a logistic regression model was 0.79 (95% CI 0.66 - 0.91) (p=0.0016 under a one-sided bootstrap test comparing the two AUCs), sensitivity 0.67 (95% CI 0.50 -0.83), PPV 0.32 (95% CI 0.26 - 0.38) and NPV of 0.97 (95% CI 0.96 - 0.99) at 90% specificity (see Supplementary Table 3). Amongst all biomarkers, CA19-9 demonstrated the most significant association (refer to Supplementary Table 3 and Supplementary Figure 1 for univariate trend associations across the discovery set), and one of the highest performances in the validation set (Supplementary Figure 1 and Supplementary Table 4).

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

403

In the validation set, the ensemble signature predicted PDAC with an AUC of 0.95 (95% CI 0.91 – 0.99), sensitivity 0.86 (95% CI 0.68 - 1), PPV 0.54 (95% CI 0.48 - 0.58) and NPV of 0.98 (95% CI 0.95 - 1) at 90% specificity. Once again, this is an improvement with respect to CA19-9 (p=0.0082, one-sided bootstrap test) taken as a univariate model developed in the discovery set; this CA19-9 model predicted PDAC status with an AUC of 0.80 (95% CI 0.66 – 0.93), sensitivity 0.65 (95% CI 0.48 - 0.56), PPV 0.49 (95% CI 0.41 - 0.56) and NPV of 0.95 (95% CI 0.92 - 0.98) at 90% specificity in the validation set. If we further validate only on the benign disease controls and PDACs collected from ADEPTS, the diagnostic-specific ensemble signature achieved an AUC of 0.96 (95% CI 0.92 – 0.99), sensitivity 0.82 (95% CI 0.64 – 0.95) at 90% specificity. This performance is also significantly higher than the performance of CA19-9 in a univariate model: AUC of 0.79 (95% CI 0.64-0.93) (p= 0.013 when compared with the full signature, one-sided test) and sensitivity of 0.18 (95% CI 0.03 – 0.69).

A closer examination of the individual performances of each base-learner classifier (Figure 2A and B) reveals that the logistic regression stacked ensemble approach has superior performance in both discovery and validation sets. Despite the best base-learner being trained on samples diagnosed as 'Gastritis/Reflux Disease' (Figure 2A and B), its performance was also superseded by the AUC computed with the stack model, the logistic regression coefficients of which are delineated in Supplementary Table 5. The stack model significantly relies on the "Healthy", "Chronic Pancreatitis", "IgG4 Disease", "Irritable Bowel Syndrome", 'Other Biliary Duct Disease", "Sphincter of Oddi Dysfunction", "No Relevant Diagnosis", "Other Cancer" and "Pancreatic Cyst" base-learners. Even though the remaining diagnostic class base-learners, including "Gastritis/Reflux Disease", did not reach statistical significance (p<0.05), employing a stack that solely resorts to significant base-learners led to a reduction in generalization capacity: AUC 0.98 (95% CI 0.97 - 0.99), sensitivity 0.98 (95% CI 0.95 -1), PPV 0.92 (95% CI 0.91 – 0.92), NPV 0.97 (95% CI 0.94 – 0.99) in the discovery set; AUC 0.93 (95% CI 0.87 - 0.99), sensitivity 0.82 (95% CI 0.64 - 0.95), PPV 0.53 (95% CI 0.47 - 0.57), NPV 0.97 (95% CI 0.95 – 0.99) in the validation set. Although the differences are not substantial, we retain the full set of base-learners to enhance the generalization capacity for predicting PDAC in unseen data sets and new samples.

The employment of stacked diagnosis-specialized classifiers surpassed the AUC performance of state-of-the-art algorithms such as random forests (RRF) and extreme gradient boosting methods (xgbTree), in terms of AUC, sensitivity, positive predictive value, and negative predictive value at 90% specificity (Figure 2C and D); although the performance AUC of the stacked classifier was only marginally significantly higher than that obtained with RRF (p=0.040, one-sided) and not significant when compared with xgbTree (p=0.26, one-sided), the sensitivity values at 90% specificity obtained with the alternative methods were, in fact, significantly lower, p=0.028 and p=0.045, respectively. The ensemble also outperformed a logistic regression model with recursive feature elimination (Figure 2C and D) that did not rely on ensemble modelling (p=0.0066, one-sided), further substantiating our choice of machine learning paradigm for facilitating the identification of PDAC cases in a clinical setting where confounding diagnoses may be present, and the prevalence is low.

The comprehensive index signature, incorporating all diagnostic categories, was constituted by 49 features, of which 44 were proteins (see Figure 3 for the importance associated with each). Among these proteins, 21 demonstrated a significant association with PDAC in the discovery set; ICOSLG, GPNMB, ESM-1, DLL1, VWF, ERBB2, FCRLB, CEACAM5, EGF, CTSV, FASLG, Creatinine, CPE, CA9/CAIX, TBIL, CD207, CRP, CDKN1A, EPHA2, ITGAV, and MUC-16 (see Supplementary Figure 1 and Supplementary Tables 3). The remaining 23 proteins, namely CXCL13, ERBB3, FOLR1/FR-alpha, FADD, ERBB4, CD27, AREG/AR, ADAM-TS-15, ABL1, ANXA1, CXCL17, CD70, CEACAM1, CD48, IL6ST, CD160, PKM/PKM2, CYR61/CCN1, CRNN, ADAM-8, FOLR3/FRgamma, THBS2, GZMB, did not demonstrate a significant association with PDAC in univariate models (see Supplementary Figure 1 and Supplementary Tables 3 and 4). Additionally, five clinical covariates—Gender, Age, Ethnicity, Diabetes, and Body Mass Index (BMI)—were identified as important predictors following comprehensive recursive feature elimination during cross-validation (Figure 3).

Gene Ontology (GO) and biological pathway enrichment (Kyoto Encyclopaedia of Genes and Genomes; KEGG, Reactome Pathway Database; REAC and WikiPathways; WP) analysis was performed for the selected set of features using g:Profiler (Supplementary Figure 3). Top significant terms for biological processes (BP) included 'circulatory system development', 'blood vessel morphogenesis', 'cell adhesion', 'angiogenesis', 'blood vessel development', 'regulation of cell adhesion', 'positive regulation of cell population proliferation', 'cell-cell adhesion', and 'regulation of

developmental process'. Top relevant biological pathways included: 'Pl3K-KAT signalling pathway', 'ERBB signalling pathway', 'pathways in cancer', 'proteoglycans in cancer', 'platinum drug resistance', 'prostate cancer', 'type I diabetes mellitus', 'MAPK signalling pathway' and 'focal adhesion'.

The scaled importance of each feature and diagnostic class/classifier is depicted in Figure 3. It is of significance to note that not every biomarker was selected by each individualized classifier, highlighting the requirement for an array of diverse predictors, each tailored to specific underlying conditions, to effectively identify PDAC. This is consistent with the idea that heterogeneous ensembles are fundamental for predictive capacity in blind datasets (36, 43).

Of the five selected clinical covariates, only Age, Ethnicity, and Gender manifested as significant predictors of PDAC in the validation set, as illustrated in Figure 1 and explained in the data set characteristics subsection (see also Supplementary Table 6 and 7). It is worth emphasizing that the lack of significant association between certain markers and PDAC in the discovery set does not preclude their inclusion in the signature. These variables were selected due to their contribution to the enhanced robustness and generalization capacity in predicting PDAC during cross-validation with a recursive feature elimination routine (see Methods). A similar trend was verified in prior work focussed on ensemble models for PDAC early detection against healthy controls (36).

# Application of a reduced, 8-marker signature as a differentiator of PDAC from healthy and benign controls

Across all conditions, 8 features with relatively higher scaled importance that differentiated controls from PDAC patients were selected (Figure 3). Importance is measured by the contribution of a specific feature to the output of the model (see Methods), in our case the probability of PDAC. These included CA19-9, VWF, CPE, CTSV, CEACAM1 and CD160 together with Diabetes and Age as clinicodemographic variables. Diabetes was a predictor of the differences between PDAC against familial cases, gastric reflux disease (GORD), sphincter of oddi (SOD) dysfunction, as well as healthy controls.

CA19-9 levels were only selected as a top discriminating feature against PDACs in patients with suspected sphincter of Oddi dysfunction, benign liver disease, irritable bowel syndrome (IBS), those with isolated LFT derangements as well as distinguished healthy subjects and those with other cancers (Figure 3 and Supplementary Table 8), from PDAC patients.

Von Willebrand Factor (VWF) levels differentiated PDAC from symptomatic patients with pancreatic cysts, benign biliary duct diseases, non-abdominal conditions, patients with family history of PDAC, those with GORD as well as healthy subjects.

The immunoglobulin like surface antigen molecule CD160 (peripheral natural killer cells and CD8<sup>+</sup> T lymphocytes) (52) and a proposed immune checkpoint inhibitor, was selected as a significant differentiator of PDAC from benign biliary tract diseases (IgG4 disease), SOD dysfunction, IBS as well as in familial pancreatic cancer subjects and other cancers. Cathepsin V (CTSV) levels were also a predictor of multiple conditions against PDAC, including benign biliary diseases and in subjects belonging to the familial PC cohort. In healthy subjects, however, this feature did not show significant importance as a differentiator from PDAC.

Serum levels of the metallo-carboxypeptidase E (CPE) were a feature selected as significant in five conditions (acute pancreatitis, gallstones and IgG4 disease, SOD dysfunction and GORD) as well as a differentiator in those with FH of PC. A higher scaled importance was attributed to this enzyme against CA19-9 when differentiating acute and chronic pancreatitis (CP), isolated LFT derangements, unexplained abdominal pain and non-abdominal conditions versus PDAC (Figure 3).

THE CEA cell adhesion molecule (CEACAM1) was selected as a feature in patients with non-explained recurrent abdominal pain, isolated LFT derangements, GORD, SOD dysfunction as well as a feature selected against non-pancreatic cancers.

Chronic pancreatitis (CP) is a known risk factor for PDAC. In our index signature, the protein markers selected against PDAC included ESM1, ICOSLG, CTSV, CXL17 (CXC motif chemokine ligand 17), IL6ST, ITGAV, GZMB (granzyme B; secreted serine protease), with a reduced risk for cancer in Caucasian ethnicity (53-55).

524

525

526

527

528

529

530

531

532

533

534

535

536

537

538

539

540

541

542

543

We therefore opted to assess their combined performance against CA19-9 as a single marker. Using a similar stacking procedure as before, a reduced model was trained using the same ensemble approach as that highlighted before but with only 8 features as the input. The reduced signature predicted PDAC still with a high AUC value of 0.97 (95% CI 0.95-0.98), sensitivity 0.98 (95% CI 0.95-1), PPV 0.92 (95% CI 0.91-0.92) and NPV of 0.98 (95% CI 0.94-1) at 90% specificity, in the discovery set (Supplementary Figure 4C). In the validation set, however, the performance of the 8-marker signature was significantly reduced (p= 0.00038, one-sided) compared to the full stacked model (AUC of 0.84 (95% CI 0.75-0.94), sensitivity 0.64 (95% CI 0.36-0.82), PPV 0.47 (95% CI 0.33-0.53) yet with a NPV of 0.95 (95% CI 0.91-0.97) at 90% specificity (Supplementary Figure 4D)), and only marginally superior to CA19-9 as a single marker (p=0.18, one-sided). On the other hand, the 8-marker signature still outperformed CA19-9 by a relatively large margin when predicting PDAC against healthy UKCTOCS controls in the validation set: AUC<sub>redsig</sub> of 0.93 (95% CI 0.84 - 1), sensitivity<sub>redsig</sub> of 0.86 (95% CI 0.54 - 1), PPV<sub>redsig</sub> 0.94 (95% CI 0.90 -0.94), NPV<sub>redsiq</sub> 0.80 (95% CI 0.54 - 1); AUC<sub>CA19-9</sub> of 0.84 (95% CI 0.70 - 0.97), sensitivity <sub>CA19-9</sub> of 0.68 (95% CI 0.5 – 0.91), PPV CA19-9 0.92 (95% CI 0.89 – 0.94), NPV CA19-9 0.62 (95% CI 0.52 – 0.85), at 90% specificity. Under a bootstrap test this AUC difference is significant p= 0.025 (one-sided). In addition, it also outperformed the full PDAC ensemble model when predicting PDAC against healthy controls in the validation set, although the differences were not significant (p=0.2, one-sided): AUC<sub>sig</sub> of 0.90 (95% CI 0.77 - 1), sensitivity<sub>sig</sub> of 0.86 (95% CI 0.54 - 1), PPV<sub>sig</sub> 0.94 (95% CI 0.92 - 0.94), NPV<sub>sig</sub> 0.80 (95% CI 0.66 – 1) at 90% specificity.

544

545

546

547

548

549

550

551

If on the other hand the reduced signature is validated in ADEPTS samples only, i.e. in PDACs plus benign disease controls, the performance of the reduced signature is far inferior to the full signature:  $AUC_{redsig} \text{ of } 0.83 \text{ (95\% CI } 0.73-0.93) \text{ (p= } 0.0009 \text{ when compared with } AUC_{sig}, \text{ one-sided test)}, \\ sensitivity_{redsig} 0.59 \text{ (95\% CI } 0.27-0.82), PPV_{redsig} 0.47 \text{ (95\% CI } 0.29-0.55) \text{ and } NPV_{redsig} 0.94 \text{ (95\% CI } 0.89-0.97), \\ at 90\% \text{ specificity}. This further justifies the use of the full ensemble signature in blind data sets and in a scenario where there is limited information on a patient trajectory, despite its increased complexity.}$ 

In consideration of the marker importance in the reduced model, no marker received a null significance across all diagnostic specific base-learners, a divergence from observations in the comprehensive signature. CA19-9 emerged with the largest average importance across conditions, which also contrasted with the full model. Age and VWF were ranked with elevated average significance across diverse conditions. It's pertinent to note that CPE levels manifested diminished scaled importance in discerning healthy controls from PDAC, particularly when juxtaposed against CA19-9, age, and CEACAM1 (refer to Supplementary Figure 5).

### Application of the full PDAC ensemble signature in symptomatic patients

Our subsequent aim was to explore whether specific clinical manifestations were correlated with PDAC status in our ADEPTS patient cohort, for which such information was available (refer to Supplementary Figure 6 and Supplementary Table 9). As a similar type of data was not available for the UKCTOCS subset (healthy controls) used in this work, we focussed this section on the ADEPTS cohort.

In our prior research, we analysed 12 "red-flag" symptoms reported by patients up to 22 months before the diagnosis of pancreatic cancer was established (20). In this work, 'Vomiting' (p=0.17), 'Asymptomatic LFT Derangement' (p=0.28), 'Back pain' (p=0.54), 'Change in Bowel Habit' (p=0.67) and 'Rectal Bleeding' (p=0.76) were selected for PDAC (versus benign disease controls), yet only 'Jaundice' (p=3.22×10<sup>-15</sup>), and 'Weight Loss' (p=1.44×10<sup>-6</sup>) were significantly associated with PC cancer cases in the set of samples randomly selected from the ADEPTS cohort, in which the biomarker panel was tested (Figure 4B and Supplementary Table 9). Unsurprisingly, 'Reflux' (p=0.022) and 'Bloating' (p=0.048) were significantly associated with benign controls. Interestingly, 'Abdominal Pain', 'Heartburn', 'Anaemia', and 'Dysphagia' upon presentation were aligned more with the benign control cohort, albeit not significantly (refer to Figure 4 and Supplementary Table 9).

Within the framework presented in preceding sections, our ensemble of classifiers was developed independently of symptomatic data. To assess the overall efficacy of our signature and its predictive capacity for PDAC, we scrutinized its performance on a subset of ADEPTS patients, belonging to both discovery and validation cohorts, manifesting with 'Weight Loss' (n=56) and 'Jaundice' (n=40) (refer to

Figure 4 and Supplementary Table 9). For each sample within these cohorts, where symptom data was accessible, probability scores were derived based on the ensemble model formulated using the whole discovery set presented above. We should emphasize that no additional model refinement was pursued. The decision to aggregate these probability scores is further rationalized by the relatively limited patient count exhibiting 'Weight Loss' and 'Jaundice' within the individual discovery and validation datasets (Supplementary Table 9). In the ADEPTS subset of samples presenting with 'Weight Loss', an AUC of 0.95 (95% CI 0.90 - 0.1), a sensitivity of 0.94 (95% CI 0.29 - 1), a PPV of 0.80 (95% CI 0.56 - 0.81), and a NPV of 0.97 (95% CI 0.74 - 1) at 90% specificity were achieved (Table 2 and Figure 5). In patients presenting with 'Jaundice', an AUC of 0.89 (95% CI 0.79 - 0.99), a sensitivity of 0.73 (95% CI 0.36 - 0.91), a PPV of 0.90 (95% CI 0.82 - 0.92), and a NPV of 0.73 (95% CI 0.54 - 0.89), at 90% specificity, were observed (Table 2 and Figure 5). Compared with the AUC obtained with a simple CA19-9 logistic regression model developed in the discovery set and by concatenating the probability scores in the discovery and validation as done above, a significantly lower AUC of 0.74 (95% CI 0.58 - 0.90) is achieved (p=1.29×10<sup>-11</sup>, one-sided bootstrap test), with a sensitivity of 0.53 (95% CI 0.24 - 0.76), a PPV of 0.70 (95% CI 0.50 - 0.77), and a NPV of 0.81 (95% CI 0.73 - 0.90), at 90% specificity, for patients presenting with 'Weight Loss'. For patients presenting with 'Jaundice' an AUC of 0.70 (95% CI 0.53 - 0.86) is reached, also significantly inferior (p=  $1.94 \times 10^{-7}$ ), with a sensitivity of 0.41(95% CI 0.14 - 0.73), a PPV of 0.83 (95% CI 0.64 - 0.90), and a NPV of 0.55 (95% CI 0.46 - 0.73), at 90% specificity, for CA19-9 as the single predictor.

With respect to other non-localising symptoms of note (Figure 5, Table 2 and Supplementary Table 10), the best predictive performance was noted for the full index signature where it was able to differentiate patients presenting with 'abdominal pain' due to benign conditions vs. PDAC with an AUC of 0.98 (95% CI 0.97-1), sensitivity of 0.94 (95% CI 0.81-1), PPV 0.43 (95% CI 0.40-0.45) and a NPV of 0.99 (95% CI 0.98-1), at 90% specificity. In those presenting with 'change in bowel habit', an AUC of 0.97 (95% CI 0.92-1), sensitivity 0.86 (95% CI 0.81-1), PPV of 0.51 (95% CI 0.41-0.55) and NPV of 0.98 (95% CI 0.95-1) was obtained. Both the index and the 8-marker signature showed superior predictive performance to CA19-9 as a single marker (see Supplementary Table 11 for the respective p-values).

### Correlation of the full PDAC ensemble signature with QCancer pancreatic score

In our final analysis, we juxtaposed the performance of our full ensemble classifier PDAC index against the QCancer risk prediction index, a clinical decision support tool available for primary care physicians, that integrates a myriad of individual-specific risk factors including age, sex, ethnicity, clinical measurements, diagnoses, and patient-reported symptoms into a risk stratifying point of care questionnaire (47). The 'Today's QCancer' index evaluates an individual's current risk of having an undiagnosed cancer as well as the specific risk for 9 distinct underlying cancer types, including pancreatic ('pancreatic' score) (56, 57). The aim was to determine whether in combination, the QCancer eCDST and our biomarker index signature would be able to better discriminate PDAC patients in a symptomatic (ADEPTS) cohort or whether it would be redundant. As the current risk threshold set by the NICE is at 3% for triggering specialist referrals (24), we opted to assess the combined performance of our index signature and the eCDST at a same or lower cut-off values.

The number of samples for which a QCancer score was computed is illustrated in Figure 6C. Using the diagnostic-specific ensemble model delineated previously, probability scores for samples in both discovery and validation cohorts were used to ascertain the combined ROC AUC for those samples possessing a QCancer score. This amalgamation was imperative, considering the reduced number of samples with an associated QCancer score (Figure 6C). It should be emphasized that no subsequent refinements or training of the algorithm were conducted. The ensemble stack index demonstrated a remarkable performance, achieving an AUC of 0.98 (95% CI 0.97 - 0.99), a sensitivity of 0.99 (95% CI 0.97-1), a PPV of 0.91 (95% CI 0.90 – 0.91), and a NPV of 0.99 (95% CI 0.96 - 1), at 90% specificity. Interestingly, when considering only samples with a QCancer risk above 2 or 2.5, the biomarker and clinical covariate ensemble index exhibited comparatively lower performance (Figure 6A). For a QCancer risk above 3.0, the performance of the index decreases minimally once again, which is expected as the difficulty of correctly singling out cases from confounding controls is increased (Figure 6A). However, the QCancer pancreatic score did exhibit a correlation with the odds of PDAC as determined by the ensemble classifier (R=0.36, p=3.4×10<sup>-8</sup>, Figure 6D) which highlights an important link between the purely clinical variables recorded for this cohort and the PDAC signature. Most importantly, the stacked index succeeded in attributing higher odds ratios above 1 to several PDAC cases that would have otherwise escaped detection had a QCancer score above 3 been taken as the risk predictor (Figure 6D). Contrarily, when depending exclusively on the QCancer score, and using it to calculate the ROC AUC, the predictive capacity for PDAC in the ADEPTS samples is noticeably diminished in comparison to the performance of the ensemble index (Figure 6B); this was verified in all samples with a Qcancer score (p=1.56×10<sup>-18</sup>,one-sided bootstrap test comparing AUCs), with a score above 2 (p=1.24×10<sup>-10</sup>), above 2.5 (p=3.68×10<sup>-13</sup>) and above 3 (p=2.33×10<sup>-8</sup>). This justifies the PDAC signature as a useful complementary resource for enhanced and accelerated diagnosis in the clinic.

### **Discussion**

Our objective was to construct a multi-biomarker signature that could effectively differentiate individuals with non-specific yet concerning symptoms attributable to both benign abdominal pathologies and PDAC. CA19-9 tumour marker blood levels are used clinically to help confirm PDAC diagnosis in a clinical context (positive findings on imaging, histopathology), prognosticate and monitor recurrence following tumour resections (58). Its absent expression in Lewis body negative blood group individuals, an overall limited predictive capacity (79–81% test sensitivity and 82–90% specificity at best) and especially in the presence of certain inflammatory pancreatico-biliary conditions, have driven researchers to rather combine it in multi-marker panels to enhance its predictive performance (29, 30, 58). In an evolving multi-omics area, reported panels have included proteins, circulating nucleic acids (micro-RNA, cfDNA) or tumours cells, metabolites, and products of alternative DNA splicing and methylations (58, 59), developed to differentiate PDAC from healthy and those with benign pathologies. Yet, the role of such diagnostic and screening panels in symptomatic cohorts remains unestablished.

The sampled population in our study is an enriched, symptomatic, secondary care cohort where the prevalence of PDAC was close to 8%, representing figures observed in our hepatobiliary specialised referral centres. By using this target population and their unique set of serum samples provided by the ADEPTS study (33), we were able to develop a biomarker signature in a cohort of patients who were referred to our participating centres (University College London Hospitals, London UK and the Royal Free Hospital, London UK) with various abdominal and hepatobiliary conditions which in symptomatic presentation might overlap with PDAC (20). Moreover, we included samples from patients with known risk factors for PC (chronic pancreatitis, those with family history of PDAC and cystic lesions of the

pancreas, CLPs) and with biliary conditions that are known confounders of CA19-9 (i.e. biliary tract inflammation/obstruction, pancreatitis, CLPs) - the only tumour marker clinically applied in the workup and management (29, 39, 60) of PDAC.

We employed ensemble methods, which have achieved impressive accuracy in numerous complex classification tasks (36, 42, 43, 61). Specifically, we utilized stacking—a form of meta-learning (43)—to create a superior-level predictive model based on the predictions of diagnostic-specific base classifiers. These classifiers leveraged a diverse set of features, highlighting the fundamental importance of heterogeneity arising from specific diagnoses when compared against PDAC, an approach previously demonstrated to be effective (36, 42). Moreover, this study enabled us to evaluate the specificity of our early detection machine learning approach (36) within a relevant symptomatic population, thereby allowing us to address confounding factors that may impact their performance. The use of such diagnostic specialized base-learners was further justified by the data asymmetry between PDAC cases and controls observed in both the discovery and validation datasets.

Across all diagnosis classes (base learners) the index signature which comprised 44 clinical and serum protein covariates predicted PDAC (all stages) with an AUC of 0.98 (95% CI 0.98 - 0.99); at 90% specificity, a sensitivity of 0.99 (95% CI 0.98 - 1), PPV 0.92 (95% CI 0.91 - 0.92) and NPV 0.99 (95% CI 0.97 - 1) was reached, in contrast to CA19-9 as a single predictor under a logistic regression model - AUC 0.79 (95% CI 0.66 - 0.91), sensitivity 0.67 (95% CI 0.50 - 0.83), PPV 0.32 (95% CI 0.26 - 0.38) and NPV of 0.97 (95% CI 0.96 - 0.99). On validation, an AUC of 0.95 (95% CI 0.91 - 0.99), sensitivity 0.86 (95% CI 0.68 - 1), PPV 0.54 (95% CI 0.48 - 0.58) and NPV of 0.98 (95% CI 0.95 - 1) was achieved by the signature, compared to an AUC of 0.80 (95% CI 0.66 - 0.93), sensitivity 0.65 (95% CI 0.48 - 0.56), PPV 0.49 (95% CI 0.41 - 0.56) and NPV of 0.95 (95% CI 0.92 - 0.98), for CA19-9.

The performance of this index panel must be appreciated within the context of the complex biology associated with each of the ensembled diagnostic classes, i.e., the challenges associated with biomarker alterations on the background of pancreatico-biliary inflammatory and obstructive pathologies. When applying a redacted, 8-marker signature (CA19-9, VWF, CPE, CTSV, CEACAM1,CD160, Diabetes and Age) - features that were selected with relatively high importance

across most base learners, the performance was naturally reduced, yet still performed significantly better against CA19-9 as a single marker during discovery. Using the general linear model stack as was done in the case of the full index, the reduced signature predicted PDAC with AUC of 0.97 (95% CI 0.95-0.98), sensitivity 0.98 (95% CI 0.95-1), PPV 0.92 (95% CI 0.91-0.92) and NPV of 0.98 (95% CI 0.94-1), at 90% specificity (Supplementary Figure 4C), values comparable to the full index. During validation, however, the predictive capacity of the reduced signature was significantly reduced compared to the full stacked model (Supplementary Figure 4D) and only marginally superior to CA19-9 alone across the cohort. In contrast, it still outperformed CA19-9 by a significant margin when predicting PDAC against healthy controls.

As validation of its performance, we also applied the full index signature to the cohort, which were restratified based on presenting symptoms in contrast to the ensemble of classifiers which were developed independently of symptomatic data and with no further model refinement. The aim was to test the signature performance in differentiating PDAC cases from controls by accounting for presenting symptoms, and which have been linked with repeated primary care consultations up to two-years prior to PDAC diagnosis (20) (Figure 4). Enriched by fulfilling certain sociodemographic, clinical and attributable suspicious symptom (identified using CDSTs such as QCancer tool), symptomatic patients would form an ideal cohort for further risk stratification by minimally invasive blood biomarker testing for prioritisation of more invasive (and costly) investigations. Yet, contrary to the full index, in the cohort used in the current work the QCancer score used as the sole predictor of PDAC did not achieve significant performances in samples above the threshold of 3%. This further motivates the recourse to combined strategies where complementary biomarker panels such as those identified by ensemble modelling approaches could improve early detection when used in conjunction with CDSTs.

In our test subjects, however, only 'Jaundice' (p=3.22×10<sup>-15</sup>), and 'Weight Loss' (p=1.44×10<sup>-6</sup>) were significantly associated with PDAC. When testing the diagnostic performance of the full index signature in all symptomatic patients presenting with 'Weight Loss', the signature significantly outperformed CA19-9: AUC<sub>signature</sub> of 0.95 (95% CI 0.90 - 0.1) vs. AUC<sub>CA19-9</sub> of 0.74 (95% CI 0.58 - 0.90) (Figure 5A, Table 2 and Supplementary Table 11). 'Weight loss' has previously been reported to have the longest diagnostic interval in a prospective primary cohort study (SYMPTOM pancreatic study), assessing

symptom trends and associated diagnostic intervals in PC (14). Attesting to the full index signature's capacity as a rule out test in such patients, is its outstanding negative predictive value compared to that of CA19-9 (0.97 95% CI 0.75-1 vs. 0.81 95% CI 0.73-0.9, respectively) (Table 2). Similarly, the index signature performed superiorly to CA19-9 in jaundiced patients (AUC of 0.89 (95% CI 0.79 - 0.99) vs. CA19-9 AUC of 0.70 (95% CI 0.53 - 0.86), see also Supplementary Table 11), which underscores once again the increased capacity of the ensemble index to better identify PDAC in the presence of a known confounder of CA19-9 (29, 39).

While our study provides valuable insights, it is not without limitations. While the observed prevalence of PDAC in this study aligns with secondary care population trends, enhanced specificity and positive predictive value would necessitate larger cohorts with an increased number of cases. Moreover, the sample set representing the 'Healthy' control class warrants expansion to incorporate a more diverse population of both men and women. This control class, derived from the UKCTOCS samples used in a previous study (36), exclusively comprised women. Given its superior performance in predicting PDAC, as depicted in Figure 2, the inclusion of male samples within this class could further enhance the breadth of the panel of markers identified in this study. Lastly, although diabetes emerged both as a risk factor and a central clinical covariate in our signature (including in the reduced panel), we must emphasize and recognise the lack of complete (type, duration) data in the UKCTOCS cohort (36). Nevertheless, diabetes mellitus (and in particularly of new onset) is an established risk factor and therefore its inclusion as a relevant feature in the signature is of no surprise (9).

While both our index and reduced signature were superior to CA19-9 in their predictive performance and compensated for asymmetric binary classes by creating a diagnostic-specific ensemble, its complexity challenges its utilisation in clinic. Yet, in the current era of rapidly evolving assay technologies, the utilization of a complex biomarker signature comprising numerous variables has gained significant relevance. While the complexity of these biomarker signatures may pose analytical challenges, the evolving assay technologies offer the means to effectively harness their potential.

Future enhancements however, will naturally necessitate the study of larger cohorts, potentially incorporating a biomarker-contextualized machine learning perspective that accounts for sample-specific aspects related to diagnosis, a strategy employed in other cancer research domains (62). The

utilization of disease trajectory tracking and clinical history analysis (63) may also facilitate the application of advanced deep learning techniques and electronic health data. When combined with ensemble biomarker signatures taken for example in a longitudinal context (36, 64), these approaches could enhance the estimation of PDAC risk within an enriched symptomatic population.

**Data Availability**: Data requestors will need to sign a data access agreement and in keeping with patient consent for secondary use obtain ethical approval for any new analyses.

Acknowledgments: We thank the participants of the ADEPTS study and UKCTOCS trial, the management team, research nurses, interviewers, research assistants, and other staff who gathered the data that was used in this work. This research was funded by Cancer Research UK (grant C12077/A26223) and supported by the Pancreatic Cancer UK Early Diagnosis Award 2018, project "The Accelerated Diagnosis of neuroEndocrine and Pancreatic TumourS (ADEPTS)" (IRAS Number: 234637, NIHR Portfolio no. 7343), and by the National Institute for Health Research (NIHR) University College London Hospitals Biomedical Research Centre. UKCTOCS was core funded by the Medical Research Council, Cancer Research UK, and the Department of Health with additional support from the Eve Appeal, Special Trustees of Bart's and the London, and Special Trustees of University College London Hospitals. EC is supported by Cancer Research UK (C7690/A26881). UM acknowledges MRC Core funding (MC\_UU\_00004/01). SPP is supported by Cancer Research UK Early Detection and Diagnosis Programme EDDPGM-May22\100002 (CANDETECT, Co-PI Prof Fiona Walter).

**Author contributions**: AN, NRN, SPP, UM and AZ conceived the study. SPP, AZ and UM secured funding. NRN constructed the models, performed the statistical analysis and produced the figures. AN and NRN interpreted the data in collaboration with SPP and AZ. AN, NRN, SPP and AZ drafted the paper. ES and AN performed the experiments for all in-house biomarkers. All authors contributed to data acquisition and interpretation, and critically reviewed and approved the article:

AN, NRN, ES, PA, OB, HJW, EC, AGM, NRW, UM, GKF, AZ, SPP.

**Competing interests**: The authors declare the following competing interests: UM reports stock ownership in Abcodia UK between 2011 and 2021; UM has received grants from the Medical Research

Council (MRC), Cancer Research UK, the National Institute for Health Research (NIHR), the India Alliance, NIHR Biomedical Research Centre at University College London Hospital, and The Eve Appeal; UM currently has research collaborations with iLOF, RNA Guardian and Micronoma, with funding paid to UCL; UM holds patent number EP10178345.4 for Breast Cancer Diagnostics; AG currently has research collaborations with Micronoma and iLoF, with the research funding awarded to UCL. No other potential conflicts of interest were disclosed by any of the authors.

### 814 Tables:

**Table 1. Cohort characteristics.** The data set used to develop and test the classifiers is a combination of samples collected from ADEPTS cohort and selected controls from the UKCTOCS cohort. BMI: Body Mass Index. See Study Design in Materials and Methods section for additional details. Odds ratio (OR) and respective 95% confidence intervals are also provided in the p value column.

ADEPTS			
No. samples	46	421	
Stage I Stage II Stage III Stage IV Unknown	4 15 10 16 1	- - - -	-
Mean age at sample draw (yr) (range)	69.72 (43.00-91.00)	57.44 (19.00-93.00)	2.47×10 <sup>-7</sup> OR= 1.06 (1.04 – 1.09)
Mean BMI (kg/m2) (range)	24.84 (12.04-41.35)	25.30 (15.22-39.45)	0.47 OR=0.97 (0.88 – 1.06)
Gender Male	31	180	
Female	15	241	0.0015 OR=2.72 (1.46 – 5.27)
Diabetes			
Yes	10 (8Type II, 1 Type I, 1 unspecified)	75 (34 Type II, 41 unspecified)	0.44 OR=1.34 (0.62 – 2.70)
No	36	346	
Ethnicity	24	204	
Caucasian	21	291	
Unknown	21	60	6.56×10 <sup>-4</sup>
Asian	3	30	OR=2.02 (1.34 – 3.03)
Other	2	18 22	
Afro/Caribbean	0		
UKCTOCS			
No. samples	-	72	-

Mean age at sample draw (yr) (range)	-	62.95 (50.44-76.86)	-
Mean BMI (kg/m2) (range)	-	26.53 (17.91-42.19)	-
Gender			
Male	-	-	-
Female	-	72	
Diabetes			
Yes	-	3 (3 Type II)	-
No	-	69	
Ethnicity			
Unknown	0	72	<u>-</u>

**Table 2 Performance summary for selected models in symptomatic patients.** The probability values used to calculate the performance metrics were generated with each model developed in the training set and reported in the main text. Probability values for symptomatic patients belonging to the training set and validation set were concatenated to generate the ROC curves. Only ADEPTS samples had symptoms information. A. L. Derang.: Asymptomatic LFT Derangement. B. Pain: Back Pain. C. B. Habit: Change in Bowel Habit. W. Loss: Weight Loss. 95% confidence intervals are provided in parentheses. See also Supplementary Table 10 for the explicit performance ranks according to model, symptom and metric and Figure 5.

		Symptom (Yes)				
Models	Metric	A.L.Derang.	A. Pain	A. B. Habit	W.Loss	Jaundice
	ROC	0.85 (0.62-1)	0.81 (0.65-0.96)	0.82 (0.57-1)	0.74 (0.58-0.90)	0.70 (0.53-0.86)
CA19-9	Sens90	0.75 (0.38-1)	0.69 (0.44-0.94)	0.71 (0.42-1)	0.53 (0.24-0.76)	0.41 (0.14-0.73)
CA 19-9	PPV90	0.54 (0.37-0.61)	0.36 (0.26-0.43)	0.46 (0.34-0.55)	0.70 (0.50-0.77)	0.83 (0.64-0.90)
	NPV90	0.96 (0.90-1)	0.97 (0.95-0.99)	0.96 (0.93-1)	0.81 (0.73-0.90)	0.55 (0.46-0.73)
	ROC	0.98 (0.95-1)	0.98 (0.97-1)	0.97 (0.92-1)	0.95 (0.90-1)	0.89 (0.79-0.99)
Index	Sens90	1 (0.62-1)	0.94 (0.81-1)	0.86 (0.56-1)	0.94 (0.29-1)	0.73 (0.36-0.91)
signature	PPV90	0.61 (0.49-0.61)	0.43 (0.40-0.45)	0.51 (0.41-0.55)	0.8 (0.56-0.81)	0.90 (0.82-0.92)
	NPV90	1 (0.94-1)	0.99 (0.98-1)	0.98 (0.95-1)	0.97 (0.75-1)	0.73 (0.54-0.89)
	ROC	0.97 (0.93-1)	0.92 (0.88-0.99)	0.91 (0.83-0.98)	0.92 (0.85-0.99)	0.82 (0.67-0.97)
Reduced	Sens90	1 (0.63-1)	0.81 (0.38-1)	0.57 (0.14-1)	0.71 (0.35-0.94)	0.77 (0-0.95)
signature	PPV90	0.61 (0.49-0.94)	0.40 (0.23-0.45)	0.41 (0.15-0.55)	0.75 (0.6-0.8)	0.90 (0-0.92)
	NPV90	1(0.94-1)	0.98 (0.95-1)	0.95 (0.9-1)	0.88 (0.76-0.97)	0.76 (0.42-0.94)

### 833 Figures:

Figure 1 Characteristics of the discovery and validation sets. Number of controls across the discovery and validation sets (A), number of PDAC cases per stage (B), and association of BMI, Age, Diabetes, Ethnicity and Gender with PDAC status (C-F). In C, D, E and F dot sizes correspond to odds ratios and are colour coded according to their respective values, i.e., blue if OR<1 and red if OR>1. p values were calculated according to a logistic regression model with a bias reduction method. Purple dashed lines correspond to -Log[0.05]. G Receiver Operating Curve (ROC) Area Under the Curve (AUC), Sensitivity (Sens), Positive Predictive Value (PPV) and Negative Predictive Value (NPV) at 90% Specificity (Spec) performance of single marker models, i.e. BMI and Age, in the validation set. H Similar to A but for Gender, Ethnicity and Diabetes. Performances were calculated with the respective single feature models developed in the discovery set. The ROC AUC significance threshold is also represented by a purple dashed line at 0.5. Error bars in figures corresponding to the validation set are the 95% Confidence Intervals (CI), calculated by stratified bootstrapping 2000 times. See Statistical Analysis in Methods (main text) for further details and Supplementary Table 6, 7 and 8.







Figure 2 Performance of individual base-learner classifiers, stack ensemble and state-of-the art algorithms. A Base-learners performance in the discovery set. Each base-learner classifier was developed by training with a recursive feature elimination technique (RFE) and logistic regression (glm) in samples belonging to each specific diagnosis class against the same 24 PDACs in the discovery set. The performance reported in A is, nevertheless, of each classifier in the whole discovery set. The performances reported in B correspond to the base-learners developed in the discovery set but applied to the whole validation set. In C and D the performance of the ensemble stack based on the base-learners presented in A and B, as well as of state-of-the-art algorithms (xgbTree, RRF and RFE glm) is reported in the discovery and validation sets, respectively. xgbTree, RRF and RFE glm were trained in the whole discovery set, which contrasts with the ensemble algorithm.



**Figure 3 Features selected per diagnosis class (base-learner classifiers).** The scaled importance is calculated within each base-learner (Figure 2A). Selected features are ranked from left to right according to the average scaled importance across base learners. See Figure 1, Supplementary Figure 1 and Supplementary Tables 3 and 4 for the univariate predictive performances of each of the markers in the discovery and validation sets. See Methods section for details on model-agnostic algorithm for feature importance calculation.



**Figure 4 Association between symptoms and PDAC.** A Number of subjects with each symptom according to PDAC status, case or control. **B** Association of symptoms with PDAC status, p values were calculated according to a logistic regression model with a bias reduction method. Purple dashed lines correspond to -Log [0.05]. In B dot sizes correspond to odds ratios and are colour coded according to their respective values, i.e., blue if OR<1 and red if OR>1. See also Supplementary Table 9. Only samples belonging to the ADEPS cohort were used as no information about symptoms was available for the UKCTOCS set of samples.



**Figure 5** Receiver operating curves for selected models in symptomatic patients. A Only CA19-9. **B** Full index signature. **C** Reduced index signature. The probability values used to calculate the performance metrics were generated with each model developed in the discovery set and reported in the main text. Probability values for symptomatic patients belonging to the discovery set and validation set were concatenated to generate the ROC curves. Only ADEPTS samples had symptoms information. A. L. Derang.: Asymptomatic LFT Derangement. B. Pain: Back Pain. C. B. Habit: Change in Bowel Habit. W. Loss: Weight Loss. See also Table 2 for numerical values for area under the curve and other metrics.





Figure 6 Prediction of PDAC in patients with specific symptoms and according to QCancer score values. The ensemble stack was selected as the best model according to Figure 2. A Performance of the stack in participants for which a Qscore had been calculated or above a specific threshold, bigger than 2, 2.5 or 3.0. B Performance of the Qscore taken as the predictor of PDAC risk in participants for which a Qscore had been calculated or above a specific threshold, bigger than 2, 2.5 or 3.0. C Number of subjects that had a calculated Qscore or are above a specific threshold, bigger than 2, 2.5 or 3.0. D Correlation between QCancer score and odds ratio of PDAC according to the stacked ensemble. E is in log scale. The QCancer score is identified as Qscore in the figure panels.



## **Supplementary Information**

Title: Identification of a serum proteomic biomarker panel using diagnosis specific ensemble learning and symptoms for early pancreatic cancer detection

### Authors:

Alexander Ney<sup>1,\*</sup>, Nuno R. Nené<sup>2,3,4\*</sup>, Eva Sedlak<sup>2</sup>, Pilar Acedo<sup>1</sup>, Oleg Blyuss<sup>2,5,6</sup>, Harry J. Whitwell<sup>2,7,8</sup>, Eithne Costello<sup>9</sup>, Aleksandra Gentry-Maharaj<sup>2,10</sup>, Norman R. Williams<sup>11</sup>, Usha Menon<sup>10</sup>, Giuseppe K. Fusai<sup>12</sup>, Alexey Zaikin<sup>2,13,14</sup>, Stephen P. Pereira<sup>1,\*</sup>.

### Affiliations:

<sup>&</sup>lt;sup>1</sup> Institute for Liver and Digestive Health, University College London, Upper 3<sup>rd</sup> Floor, Royal Free Campus, Rowland Hill Street, London NW3 2PF, United Kingdom


<sup>&</sup>lt;sup>2</sup> Department of Women's Cancer, EGA Institute for Women's Health, University College London, 84-86 Chenies Mews, London, WC1E 6HU, United Kingdom

<sup>&</sup>lt;sup>3</sup> Cancer Institute, University College London, 72 Huntley St, London, WC1E 6DD, United Kingdom.


945 946 947	<ul> <li>Department of Statistical Science, University College London</li> <li>1-19 Torrington Place, London, WC1E 6BT, United Kingdom</li> </ul>					
948 949 950	<sup>5</sup> Wolfson Institute of Population Health, Queen Mary University of London, Charterhouse Square, EC1M 6BQ, London, United Kingdom					
951 952	<sup>6</sup> Department of Pediatrics and Pediatric Infectious Diseases, Institute of Child's Health, Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia					
953 954	National Phenome Centre and Imperial Clinical Phenotyping Centre, Department of Metabolism, Digestion and Reproduction, IRDB, Building Imperial College London, W12 ONN, United Kingdom					
955 956 957	<sup>8</sup> Section of Bioanalytical Chemistry, Division of Systems Medicine, Department of Metabolism, Digestion and Reproduction, Sir Alexander Fleming Building, Imperial College London, SW7 2AZ, United Kingdom					
958 959 960 961	<sup>9</sup> Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, United Kingdom					
962 963 964	<sup>10</sup> MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, 90 High Holborn, 2nd Floor, London, WC1V 6LJ, United Kingdom					
965	<sup>11</sup> Division of Surgery & Interventional Science, University College London, London, United Kingdom					
966 967 968	<sup>12</sup> HPB & Liver Transplant Unit, Royal Free London, London NW3 2QG, United Kingdom					
969 970	<sup>13</sup> Institute for Cognitive Neuroscience, University Higher School of Economics, Moscow, Russia					
971 972	<sup>14</sup> Department of Mathematics, University College London, London WC1H 0AY, United Kingdom					
973 974	* These authors contributed equally to the work					
975	To whom correspondence should be addressed:					
976	Dr Alexander Ney (Email: <u>alexander.ney.15@ucl.ac.uk</u> )					
977	Dr Nuno Rocha Nené (Email: nuno.nene.10@ucl.ac.uk )					
978	Prof Stephen Pereira (Email: stephen.pereira@ucl.ac.uk)					
979						
980 981						
982						
983						
984 985	In this supplementary information we provide the additional tables and figures cited in the main text.					
986						
987						

#### **Supplementary Figures**


**Supplementary Figure 1 Biomarker ranks in the discovery set. A** Distribution and ranks of biomarkers by p values in the discovery set. Purple dashed line corresponds to -Log [0.05]. **B** Receiver Operating Curve (ROC) Area Under the Curve (AUC), Sensitivity (Sens), Positive Predictive Value (PPV) and Negative Predictive Value (NPV) at 90% Specificity (Spec) performance of single marker models in the validation set set. OR stands for oddsratio, with dot size proportional to the calculated values. Red and blue OR points represent OR > 1 (favours pancreatic ductal adenocarcinoma (PDAC) case status) and OR < 1 (favours Control status), respectively. p values were calculated according to a logistic regression model with a bias reduction method. Performances were calculated with the single feature models developed in the discovery set. The ROC AUC significance threshold is also represented by a purple dashed line at 0.5. Error bars in figures corresponding to the validation set correspond to 95% Confidence Intervals (CI), calculated by stratified bootstrapping 2000 times. See statistical analysis section in Methods (main text) for further details and Supplementary Table 3 and 4.




Supplementary Figure 2 Flow diagram for the stack ensemble classifier. The general linear stack model presented in the main text was built according to this diagram, where base-learners are trained in groups of control samples with a specific diagnosis and the same PDAC cases. The stacking procedure has 2 steps. First, the probability output vectors for each base-learner are concatenated, thus leading to n probability vectors, where n is the number of diagnosis subclasses. Second, these vectors are subsequently used to populate the diagonal blocks of a large probability matrix. The off-diagonal probability blocks are generated by using the base models trained in a specific diagnosis subclass plus the same PDACs, which therefore amounts to computing cross diagnosis predictions. The resulting large matrix has n columns and is then used to train the meta-learner which outputs the final probability vector. For the purposes of applying the resulting trained models to the validation set, the flow of the diagram is the same as before, but the feature matrix will have a different number of samples.




**Supplementary Figure 3 Enrichment analysis.** g:Profiler terms for the set of features selected by the full stack ensemble. **A** Kyoto Encyclopaedia of Genes and Genomes (KEGG) pathways. **C** Reactome Pathway Database (REAC). **E** WikiPathways (WP). **G** Gene ontology terms biological process (GO: BP). The respective adjusted p-values associated with each enrichment term or pathway are plotted in **B**, **D**, **F** and **H**. See also Figure 3. See Statistical Analysis in Methods for further details.




Supplementary Figure 4 Performance of individual base-learner classifiers and stack ensemble for a reduced set of biomarkers, CA19-9, Age, Diabetes, VWF, CPE, CTSV, CEACAM1 and CD160. A Base-learner performance in the discovery. Each base-learner classifier was developed by training with a recursive feature elimination technique (RFE) and logistic regression (glm) in samples belonging to each specific diagnosis class against the same 24 PDACs in the discovery set. The performance reported in A is, nevertheless, of each classifier in the whole discovery set. The performances reported in B correspond to the base-learners developed in the discovery set but applied to the whole validation set. In C and D the performance of an ensemble GLM stack based on the base-learners presented in A and B is reported in the discovery and validation sets, respectively. The ROC AUC significance threshold is represented by a purple dashed line at 0.5. Error bars in figures correspond to 95% Confidence Intervals (CI), calculated by stratified bootstrapping 2000 times.



S	upplementary Figure 5 Feature importance for a reduced 8-marker model following the same principles
a	s those described in Figure 2 A and B. The reduced set of biomarkers was CA19-9, Age, Diabetes, VWF, CPE,
С	TSV, CEACAM1 and CD160. See also performances in Supplementary Figure 4. Selected features are ranked
fr	om left to right according to the average scaled importance across base learners. See Methods for details.



**Supplementary Figure 6 Matrix for associated symptoms for each sample.** Each sample in the whole set collected from ADEPTS cohort is represented by the columns. The colour coding corresponds to the diagnosis class associated with each sample. Symptoms are represented in each row. Both columns and rows are clustered according to their symptoms pattern. Black represents presence of sample with the respective symptoms and diagnosis.



## 1086 Supplementary Tables 1087

Supplementary Table 1 Quantitative ELISA assays` intra-assay coefficient of variation.

Assay	Dilution factor	CV(%)
CA19-9(A)	1:4	6.9
VWF	1:100	13.5
THBS2	1:10	12.5
PKM/PKM2	1:10	10.3
IL6ST/IL6RB	1:100	-

1091

1092

1093

1094

1095

1096

1097

1099

1100

1101

1102

1103

1104

1105

1106

1107

1108

1098

provided by Olink.

**PODXL** VEGF-A VEGFR-VEGFR-3/LFT4 RSP03 IL6 IFN-2/KDR gamma-R1/IFNGR1 MIC-A/B CXCL17 MK/MDK WFDC2 ESM-1 **MSLN** CEACAM1 ITGAV GPC1 SYND1/SDC1 PVRL4/NECTIN4 TXLNA Gal-1/GAL LYPD3 CDKN1A PPY SCF/KITLG IGF1R LYN ABL1 EPHA2 EGF AREG/AR ErbB2/HER2 ErbB3/HER3 ErbB4/HER4 WISP-1/CCN4 WIF-1 TRAIL/TNFSF10 TNFSF13 TNFRSF19 **TNFRSF6B** TLR3 SMAD5/MAD5 FADD KLK8/hK8 KLK11/hK11 KLK13 KLK14/hK14 CPE XPNPEP2 CTSV TFPI-2 SCAMP3 GZMB GZMH CYR61/CCN1 ADAM8 ADAM-TS 15 **FCRLB** TCL1A CD160 CD27 CD48 CD70 CD207 ANXA1 S100A4 S100A11 VIM CRNN DLL1 SEZ6L FOLR3/FRgamma 5'-NT/NT5E LY9 CA9/CAIX FGF-BP1 **ICOSLG** FOLR1/FRalpha MIA CEACAM5/CEA SPARC HGF TGFR-FASLG/FasL MetAP 2 2/TGFRB2 CXCL13 ITGB5 RET TGF-alpha/TGFA TNFRSF4 **GPNMB FUR/FURIN** MUC16

Supplementary Table 2 Cancer-associated proteins measured on the Olink Oncology II panel used in this

project. The remaining biomarkers were done in-house. The protein names are listed to be consistent with those

1	1	1	5

Marker	OR	p value	ROC AUC	Sens at 90% Spec	PPV at 90% Spec	NPV at 90% Spec
CA19 - 9	1.85 (1.54 - 2.26)	1.87E-12	0.79 (0.66 - 0.91)	0.67 (0.5 - 0.83)	0.32 (0.26 - 0.38)	0.97 (0.96 - 0.99)
KITLG	0.23 (0.14 - 0.37)	7.95E-11	0.79 (0.68 - 0.89)	0.5 (0.29 - 0.71)	0.26 (0.17 - 0.34)	0.96 (0.95 - 0.98)
CRP	2.01 (1.59 - 2.61)	4.12E-10	0.84 (0.74 - 0.92)	0.58 (0.38 - 0.83)	0.34 (0.25 - 0.42)	0.96 (0.94 - 0.98)
VWF	3.92 (2.28 - 7.78)	1.89E-09	0.84 (0.76 - 0.9)	0.5 (0.29 - 0.71)	0.26 (0.17 - 0.34)	0.96 (0.95 - 0.98)
SDC1	4.42 (2.56 - 8.01)	8.47E-08	0.79 (0.66 - 0.89)	0.67 (0.46 - 0.83)	0.32 (0.25 - 0.38)	0.97 (0.96 - 0.99)
KDR	0.01 (0.00 - 0.07)	2.02E-07	0.8 (0.72 - 0.87)	0.42 (0.21 - 0.67)	0.23 (0.13 - 0.32)	0.96 (0.94 - 0.97)
TBIL	2.03 (1.55 - 2.75)	2.53E-07	0.72 (0.6 - 0.85)	0.54 (0.29 - 0.71)	0.32 (0.2 - 0.38)	0.96 (0.94 - 0.97)
TNFRSF6B	2.62 (1.80 - 3.94)	3.12E-07	0.75 (0.64 - 0.86)	0.5 (0.29 - 0.71)	0.26 (0.17 - 0.34)	0.96 (0.95 - 0.98)
FASLG	0.20 (0.10 - 0.39)	2.39E-06	0.77 (0.65 - 0.87)	0.46 (0.21 - 0.67)	0.25 (0.13 - 0.32)	0.96 (0.94 - 0.97)
ESM-1	4.84 (2.35 - 10.69)	5.99E-06	0.76 (0.66 - 0.84)	0.29 (0.12 - 0.5)	0.17 (0.08 - 0.27)	0.95 (0.93 - 0.96)
EPHA2	5.15 (2.56 - 10.97)	6.31E-06	0.73 (0.63 - 0.82)	0.29 (0.12 - 0.46)	0.17 (0.08 - 0.25)	0.95 (0.93 - 0.96)
RET	0.18 (0.08 - 0.38)	7.01E-06	0.78 (0.68 - 0.87)	0.42 (0.21 - 0.62)	0.23 (0.13 - 0.31)	0.96 (0.94 - 0.97)
TGFA	0.33 (0.18 - 0.55)	9.61E-06	0.79 (0.69 - 0.87)	0.33 (0.17 - 0.62)	0.19 (0.11 - 0.31)	0.95 (0.94 - 0.97)
MUC16	2.39 (1.63 - 3.65)	1.02E-05	0.72 (0.59 - 0.83)	0.38 (0.21 - 0.58)	0.21 (0.13 - 0.3)	0.95 (0.94 - 0.97)
ITGAV	0.05 (0.01 - 0.19)	1.29E-05	0.78 (0.68 - 0.87)	0.46 (0.17 - 0.67)	0.25 (0.11 - 0.32)	0.96 (0.94 - 0.97)
EGF	0.55 (0.41 - 0.72)	3.77E-05	0.79 (0.71 - 0.87)	0.5 (0.21 - 0.71)	0.26 (0.13 - 0.34)	0.96 (0.94 - 0.98)
ICOSLG	0.04 (0.01 - 0.20)	5.60E-05	0.77 (0.66 - 0.85)	0.29 (0.12 - 0.5)	0.17 (0.08 - 0.26)	0.95 (0.93 - 0.96)
CEACAM5	2.05 (1.46 - 2.94)	6.15E-05	0.72 (0.61 - 0.83)	0.33 (0.17 - 0.58)	0.19 (0.11 - 0.3)	0.95 (0.94 - 0.97)
CTSV	0.27 (0.13 - 0.54)	0.00019	0.73 (0.61 - 0.84)	0.29 (0.08 - 0.5)	0.17 (0.06 - 0.26)	0.95 (0.93 - 0.96)
TFPI2	2.91 (1.65 - 5.38)	0.00024	0.7 (0.58 - 0.8)	0.29 (0.08 - 0.5)	0.17 (0.06 - 0.26)	0.95 (0.93 - 0.96)
WIF1	0.17 (0.06 - 0.45)	0.00031	0.72 (0.61 - 0.82)	0.33 (0.12 - 0.5)	0.19 (0.08 - 0.26)	0.95 (0.93 - 0.96)
TXLNA	2.21 (1.41 - 3.51)	0.00065	0.69 (0.55 - 0.81)	0.42 (0.17 - 0.62)	0.23 (0.11 - 0.31)	0.96 (0.94 - 0.97)
LYPD3	0.24 (0.10 - 0.57)	0.0012	0.68 (0.57 - 0.79)	0.33 (0.17 - 0.58)	0.19 (0.11 - 0.3)	0.95 (0.94 - 0.97)
CA9	2.21 (1.33 - 3.68)	0.0022	0.65 (0.52 - 0.77)	0.29 (0.12 - 0.5)	0.17 (0.08 - 0.26)	0.95 (0.93 - 0.96)
FCRLB	2.24 (1.32 - 3.74)	0.0033	0.66 (0.53 - 0.78)	0.38 (0.17 - 0.58)	0.21 (0.11 - 0.3)	0.95 (0.94 - 0.97)
TCL1A	0.54 (0.35 - 0.82)	0.0033	0.68 (0.57 - 0.78)	0.29 (0.12 - 0.5)	0.17 (0.08 - 0.26)	0.95 (0.93 - 0.96)
MDK	2.42 (1.34 - 4.42)	0.0039	0.66 (0.54 - 0.77)	0.25 (0.08 - 0.46)	0.15 (0.06 - 0.25)	0.94 (0.93 - 0.96)
CDKN1A	1.82 (1.19 - 2.75)	0.0066	0.63 (0.48 - 0.76)	0.33 (0.12 - 0.5)	0.19 (0.08 - 0.26)	0.95 (0.93 - 0.96)
FURIN	0.25 (0.09 - 0.70)	0.0083	0.67 (0.54 - 0.79)	0.29 (0.08 - 0.5)	0.17 (0.06 - 0.26)	0.95 (0.93 - 0.96)
TNFSF13	4.17 (1.43 - 12.15)	0.0093	0.64 (0.54 - 0.75)	0.25 (0.08 - 0.46)	0.15 (0.06 - 0.25)	0.94 (0.93 - 0.96)
GAL	0.16 (0.04 - 0.65)	0.011	0.63 (0.51 - 0.74)	0.25 (0.08 - 0.46)	0.15 (0.06 - 0.25)	0.94 (0.93 - 0.96)
TNFSF10	0.24 (0.08 - 0.72)	0.011	0.67 (0.55 - 0.77)	0.17 (0.04 - 0.38)	0.11 (0.03 - 0.21)	0.94 (0.93 - 0.95)
CPE	0.31 (0.12 - 0.77)	0.012	0.66 (0.54 - 0.77)	0.25 (0.08 - 0.46)	0.15 (0.06 - 0.25)	0.94 (0.93 - 0.96)
WFDC2	3.02 (1.27 - 7.34)	0.012	0.64 (0.53 - 0.75)	0.21 (0.04 - 0.42)	0.13 (0.03 - 0.23)	0.94 (0.93 - 0.96)
PPY	0.74 (0.59 - 0.94)	0.014	0.67 (0.56 - 0.78)	0.21 (0.04 - 0.46)	0.13 (0.03 - 0.25)	0.94 (0.93 - 0.96)

METAP2	1.76 (1.12 - 2.77)	0.015	0.6 (0.44 - 0.74)	0.29 (0.12 - 0.5)	0.17 (0.08 - 0.26)	0.95 (0.93 - 0.96)
XPNPEP2	0.70 (0.50 - 0.93)	0.018	0.6 (0.49 - 0.7)	0.17 (0.04 - 0.33)	0.11 (0.03 - 0.19)	0.94 (0.93 - 0.95)
NECTIN4	2.71 (1.19 - 6.04)	0.018	0.61 (0.5 - 0.72)	0.21 (0.04 - 0.38)	0.13 (0.03 - 0.21)	0.94 (0.93 - 0.95)
Creatinine	0.29 (0.10 - 0.86)	0.024	0.62 (0.49 - 0.73)	0.25 (0.08 - 0.42)	0.18 (0.07 - 0.27)	0.93 (0.92 - 0.95)
KLK8	0.34 (0.13 - 0.88)	0.026	0.61 (0.47 - 0.74)	0.35 (0.08 - 0.54)	0.2 (0.06 - 0.28)	0.95 (0.93 - 0.96)
CD207	0.35 (0.13 - 0.89)	0.028	0.62 (0.51 - 0.72)	0.12 (0 - 0.29)	0.08 (0 - 0.17)	0.93 (0.93 - 0.95)
MIA	0.24 (0.07 - 0.92)	0.038	0.62 (0.49 - 0.73)	0.25 (0.08 - 0.42)	0.15 (0.06 - 0.23)	0.94 (0.93 - 0.96)
GPNMB	9.28 (1.10 - 84.13)	0.040	0.63 (0.52 - 0.74)	0.17 (0.04 - 0.38)	0.11 (0.03 - 0.21)	0.94 (0.93 - 0.95)
ERBB2	3.21 (1.06 - 9.50)	0.040	0.56 (0.41 - 0.71)	0.33 (0.17 - 0.54)	0.19 (0.11 - 0.28)	0.95 (0.94 - 0.96)
DLL1	3.06 (1.05 - 9.11)	0.041	0.58 (0.45 - 0.7)	0.25 (0.08 - 0.46)	0.15 (0.06 - 0.25)	0.94 (0.93 - 0.96)
TNFRSF19	0.45 (0.20 - 0.98)	0.044	0.65 (0.51 - 0.77)	0.33 (0.08 - 0.54)	0.19 (0.06 - 0.28)	0.95 (0.93 - 0.96)
AR	1.47 (1.00 - 2.09)	0.053	0.63 (0.51 - 0.74)	0.21 (0.04 - 0.38)	0.13 (0.03 - 0.21)	0.94 (0.93 - 0.95)
NT5E	1.76 (0.99 - 3.08)	0.053	0.63 (0.51 - 0.74)	0.17 (0.04 - 0.46)	0.11 (0.03 - 0.25)	0.94 (0.93 - 0.96)
THBS2	1.60 (0.98 - 2.69)	0.060	0.62 (0.48 - 0.75)	0.25 (0.08 - 0.46)	0.15 (0.06 - 0.25)	0.94 (0.93 - 0.96)
ADAM8	0.42 (0.16 - 1.04)	0.060	0.6 (0.48 - 0.73)	0.25 (0.08 - 0.46)	0.15 (0.06 - 0.25)	0.94 (0.93 - 0.96)
GZMB	0.57 (0.30 - 1.06)	0.077	0.61 (0.48 - 0.74)	0.25 (0.08 - 0.5)	0.15 (0.06 - 0.26)	0.94 (0.93 - 0.96)
IGF1R	0.37 (0.12 - 1.12)	0.078	0.64 (0.52 - 0.77)	0.29 (0.08 - 0.5)	0.17 (0.06 - 0.26)	0.95 (0.93 - 0.96)
PKM	1.12 (0.98 - 1.30)	0.10	0.57 (0.43 - 0.72)	0.12 (0 - 0.46)	0.1 (0 - 0.29)	0.92 (0.91 - 0.95)
KLK14	0.53 (0.25 - 1.16)	0.11	0.59 (0.48 - 0.7)	0.12 (0 - 0.29)	0.08 (0 - 0.17)	0.93 (0.93 - 0.95)
ERBB3	0.32 (0.08 - 1.32)	0.11	0.59 (0.46 - 0.72)	0.25 (0.08 - 0.42)	0.15 (0.06 - 0.23)	0.94 (0.93 - 0.96)
CRNN	0.67 (0.40 - 1.12)	0.13	0.64 (0.53 - 0.75)	0.21 (0.04 - 0.42)	0.13 (0.03 - 0.23)	0.94 (0.93 - 0.96)
FOLR3	0.85 (0.64 - 1.05)	0.14	0.57 (0.47 - 0.68)	0.12 (0 - 0.29)	0.08 (0 - 0.17)	0.93 (0.93 - 0.95)
CXCL13	0.59 (0.28 - 1.18)	0.14	0.58 (0.43 - 0.71)	0.29 (0.12 - 0.5)	0.17 (0.08 - 0.26)	0.95 (0.93 - 0.962)
SEZ6L	0.39 (0.12 - 1.39)	0.15	0.63 (0.5 - 0.75)	0.29 (0.04 - 0.46)	0.17 (0.03 - 0.25)	0.95 (0.93 - 0.96)
KLK13	0.67 (0.38 - 1.17)	0.16	0.58 (0.45 - 0.72)	0.25 (0.08 - 0.46)	0.15 (0.06 - 0.25)	0.94 (0.93 - 0.96)
S100A11	0.57 (0.23 - 1.24)	0.16	0.54 (0.42 - 0.66)	0.21 (0.08 - 0.38)	0.13 (0.06 - 0.21)	0.94 (0.93 - 0.95)
ITGB5	2.09 (0.72 - 6.18)	0.18	0.46 (0.33 - 0.59)	0.12 (0 - 0.25)	0.08 (0 - 0.15)	0.93 (0.93 - 0.94)
IL6	1.18 (0.91 - 1.46)	0.18	0.61 (0.5 - 0.72)	0.21 (0.04 - 0.38)	0.13 (0.03 - 0.21)	0.94 (0.93 - 0.95)
MICA/B	1.24 (0.91 - 1.88)	0.19	0.62 (0.49 - 0.74)	0.25 (0.08 - 0.46)	0.15 (0.06 - 0.25)	0.94 (0.93 - 0.96)
CXCL17	1.40 (0.84 - 2.30)	0.19	0.55 (0.46 - 0.65)	0.08 (0 - 0.21)	0.06 (0 - 0.13)	0.93 (0.93 - 0.94)
CD70	0.62 (0.30 - 1.27)	0.20	0.58 (0.46 - 0.69)	0.12 (0 - 0.29)	0.08 (0 - 0.17)	0.93 (0.93 - 0.95)
CD160	0.63 (0.30 - 1.28)	0.20	0.57 (0.43 - 0.7)	0.25 (0.08 - 0.46)	0.15 (0.06 - 0.25)	0.94 (0.93 - 0.96)
TLR3	0.70 (0.41 - 1.22)	0.20	0.59 (0.44 - 0.72)	0.17 (0 - 0.38)	0.11 (0 - 0.21)	0.94 (0.93 - 0.95)
VIM	0.81 (0.55 - 1.17)	0.27	0.55 (0.44 - 0.66)	0.12 (0 - 0.29)	0.08 (0 - 0.17)	0.93 (0.93 - 0.95)
IFNGR1	1.99 (0.53 - 6.82)	0.30	0.53 (0.39 - 0.65)	0.12 (0 - 0.29)	0.08 (0 - 0.17)	0.93 (0.93 - 0.95)
FGFBP1	1.70 (0.59 - 4.53)	0.32	0.54 (0.39 - 0.68)	0.21 (0.08 - 0.46)	0.13 (0.06 - 0.25)	0.94 (0.93 - 0.96)
LY9	0.64 (0.24 - 1.70)	0.36	0.56 (0.43 - 0.69)	0.25 (0.08 - 0.46)	0.15 (0.06 - 0.25)	0.94 (0.93 - 0.96)
FOLR1	0.68 (0.28 - 1.65)	0.39	0.59 (0.46 - 0.7)	0.04 (0 - 0.33)	0.03 (0 - 0.19)	0.93 (0.93 - 0.95)
MSLN	1.25 (0.74 - 2.05)	0.40	0.58 (0.49 - 0.66)	0.04 (0 - 0.17)	0.03 (0 - 0.11)	0.93 (0.93 - 0.94)
PODXL	2.39 (0.31 - 18.29)	0.40	0.53 (0.4 - 0.67)	0.21 (0.04 - 0.42)	0.13 (0.03 - 0.23)	0.94 (0.93 - 0.96)
GZMH	1.23 (0.74 - 1.95)	0.41	0.47 (0.34 - 0.6)	0.04 (0 - 0.17)	0.03 (0 - 0.11)	0.93 (0.93 - 0.94)
S100A4	0.81 (0.46 - 1.34)	0.42	0.57 (0.42 - 0.7)	0.33 (0.17 - 0.5)	0.19 (0.11 - 0.27)	0.95 (0.94 - 0.96)
ERBB4	0.64 (0.20 - 2.08)	0.45	0.57 (0.43 - 0.69)	0.12 (0 - 0.38)	0.08 (0 - 0.21)	0.93 (0.93 - 0.95)

TGFBR2	0.71 (0.28 - 1.75)	0.46	0.59 (0.45 - 0.71)	0.12 (0 - 0.29)	0.08 (0 - 0.17)	0.93 (0.93 - 0.95)
SMAD5	0.57 (0.15 - 2.95)	0.46	0.61 (0.52 - 0.71)	0.04 (0 - 0.12)	0.03 (0 - 0.08)	0.93 (0.93 - 0.94)
VEGFA	0.78 (0.38 - 1.57)	0.49	0.52 (0.39 - 0.65)	0.17 (0.04 - 0.33)	0.11 (0.03 - 0.19)	0.94 (0.93 - 0.95)
CD48	0.66 (0.19 - 2.29)	0.50	0.53 (0.4 - 0.66)	0.21 (0.04 - 0.38)	0.13 (0.03 - 0.21)	0.94 (0.93 - 0.95)
RSPO3	1.16 (0.67 - 1.86)	0.57	0.49 (0.38 - 0.59)	0 (0 - 0)	0 (0 - 0)	0.93 (0.93 - 0.93)
CCN4	0.82 (0.38 - 1.64)	0.59	0.55 (0.42 - 0.68)	0.17 (0.04 - 0.33)	0.11 (0.03 - 0.19)	0.94 (0.93 - 0.95)
IL6ST	0.87 (0.60 - 2.13)	0.59	0.66 (0.52 - 0.8)	0.38 (0.21 - 0.58)	0.21 (0.13 - 0.3)	0.95 (0.94 - 0.97)
LYN	1.22 (0.39 - 2.70)	0.69	0.53 (0.38 - 0.67)	0.25 (0.08 - 0.42)	0.15 (0.06 - 0.23)	0.94 (0.93 - 0.96)
SCAMP3	0.94 (0.68 - 1.26)	0.70	0.5 (0.38 - 0.62)	0 (0 - 0)	0 (0 - 0)	0.93 (0.93 - 0.93)
CCN1	1.11 (0.62 - 2.02)	0.72	0.52 (0.4 - 0.63)	0 (0 - 0)	0 (0 - 0)	0.93 (0.93 - 0.93)
SPARC	0.61 (0.05 - 9.54)	0.72	0.48 (0.37 - 0.59)	0 (0 - 0)	0 (0 - 0)	0.93 (0.93 - 0.93)
TNFRSF4	1.13 (0.55 - 2.19)	0.73	0.5 (0.37 - 0.64)	0.17 (0.04 - 0.38)	0.11 (0.03 - 0.21)	0.94 (0.93 - 0.95)
ABL1	0.92 (0.55 - 1.46)	0.75	0.48 (0.34 - 0.6)	0.08 (0 - 0.21)	0.06 (0 - 0.13)	0.93 (0.93 - 0.94)
CEACAM1	0.83 (0.34 - 4.06)	0.75	0.54 (0.42 - 0.65)	0.17 (0 - 0.29)	0.11 (0 - 0.17)	0.94 (0.93 - 0.95)
FADD	1.07 (0.65 - 1.64)	0.79	0.55 (0.42 - 0.66)	0.08 (0 - 0.25)	0.06 (0 - 0.15)	0.93 (0.93 - 0.94)
ADAMTS15	1.09 (0.58 - 2.06)	0.79	0.51 (0.39 - 0.64)	0.12 (0 - 0.25)	0.08 (0 - 0.15)	0.93 (0.93 - 0.943)
CD27	1.09 (0.45 - 2.58)	0.84	0.52 (0.39 - 0.65)	0.12 (0 - 0.29)	0.08 (0 - 0.17)	0.93 (0.93 - 0.95)
HGF	1.05 (0.47 - 2.22)	0.91	0.55 (0.41 - 0.7)	0.25 (0.08 - 0.42)	0.15 (0.06 - 0.23)	0.94 (0.93 - 0.96)
KLK11	0.96 (0.40 - 2.23)	0.92	0.49 (0.39 - 0.61)	0.08 (0 - 0.25)	0.06 (0 - 0.15)	0.93 (0.93 - 0.94)
ANXA1	0.98 (0.63 - 1.51)	0.94	0.51 (0.39 - 0.63)	0.04 (0 - 0.17)	0.03 (0 - 0.11)	0.93 (0.93 - 0.94)
FLT4	0.95 (0.18 - 5.70)	0.96	0.52 (0.4 - 0.65)	0.08 (0 - 0.21)	0.06 (0 - 0.13)	0.93 (0.93 - 0.94)
GPC1	1.00 (0.37 - 2.75)	1.00	0.54 (0.41 - 0.67)	0.17 (0.04 - 0.33)	0.11 (0.03 - 0.19)	0.94 (0.93 - 0.95)
					•	

Supplementary Table 4 ROC AUC, sensitivity (Sens), positive predictive value (PPV) and negative predictive value (NPV) in the validation set of the univariate logistic regression model derived in the discovery set. Markers are ranked according to their respective p values in the discovery set (see Supplementary Table 3). Spec: specificity.

Marker	ROC AUC	Sens at 90% Spec	PPV at 90% Spec	NPV at 90% Spec
CA19 - 9	0.80 (0.66 - 0.93)	0.65 (0.48 - 0.87)	0.49 (0.41 - 0.56)	0.95 (0.92 - 0.98)
KITLG	0.82 (0.72 - 0.90)	0.48 (0.22 - 0.70)	0.41 (0.24 - 0.50)	0.92 (0.89 - 0.95)
CRP	0.85 (0.76 - 0.92)	0.59 (0.32 - 0.86)	0.47 (0.32 - 0.56)	0.94 (0.90 - 0.98)
VWF	0.74 (0.64 - 0.84)	0.26 (0.04 - 0.52)	0.27 (0.06 - 0.43)	0.89 (0.87 - 0.93)
SDC1	0.72 (0.59 - 0.83)	0.30 (0.09 - 0.61)	0.31 (0.11 - 0.47)	0.90 (0.87 - 0.94)
KDR	0.77 (0.67 - 0.86)	0.39 (0.17 - 0.61)	0.36 (0.20 - 0.47)	0.91 (0.88 - 0.94)
TBIL	0.67 (0.55 - 0.77)	0.23 (0.09 - 0.41)	0.25 (0.12 - 0.38)	0.89 (0.87 - 0.91)
TNFRSF6B	0.72 (0.60 - 0.83)	0.39 (0.13 - 0.61)	0.36 (0.16 - 0.47)	0.91 (0.88 - 0.94)
FASLG	0.74 (0.64 - 0.84)	0.26 (0.09 - 0.52)	0.27 (0.11 - 0.43)	0.89 (0.87 - 0.93)
ESM1	0.73 (0.62 - 0.82)	0.30 (0.13 - 0.52)	0.31 (0.16 - 0.43)	0.90 (0.88 - 0.93)
EPHA2	0.70 (0.56 - 0.82)	0.39 (0.17 - 0.61)	0.36 (0.20 - 0.47)	0.91 (0.88 - 0.94)
RET	0.69 (0.59 - 0.78)	0.26 (0.09 - 0.43)	0.27 (0.11 - 0.39)	0.89 (0.87 - 0.92)
TGFA	0.71 (0.59 - 0.81)	0.26 (0.09 - 0.48)	0.27 (0.11 - 0.41)	0.89 (0.87 - 0.92)
MUC16	0.71 (0.58 - 0.84)	0.48 (0.22 - 0.70)	0.41 (0.24 - 0.50)	0.92 (0.89 - 0.95)
ITGAV	0.77 (0.67 - 0.85)	0.39 (0.13 - 0.57)	0.36 (0.16 - 0.45)	0.91 (0.88 - 0.94)
EGF	0.74 (0.61 - 0.85)	0.52 (0.13 - 0.70)	0.43 (0.16 - 0.50)	0.93 (0.88 - 0.95)

ICOSLG	0.69 (0.59 - 0.79)	0.30 (0.09 - 0.48)	0.31 (0.11 - 0.41)	0.90 (0.87 - 0.92)
CEACAM5	0.72 (0.60 - 0.83)	0.35 (0.13 - 0.52)	0.33 (0.16 - 0.43)	0.91 (0.88 - 0.93)
CTSV	0.74 (0.63 - 0.84)	0.26 (0.09 - 0.57)	0.27 (0.11 - 0.45)	0.89 (0.87 - 0.94)
TFPI2	0.67 (0.54 - 0.78)	0.22 (0.04 - 0.48)	0.24 (0.06 - 0.41)	0.89 (0.87 - 0.92)
WIF1	0.63 (0.51 - 0.74)	0.17 (0.00 - 0.39)	0.20 (0.00 - 0.36)	0.88 (0.86 - 0.91)
TXLNA	0.64 (0.51 - 0.75)	0.22 (0.09 - 0.43)	0.24 (0.11 - 0.39)	0.89 (0.87 - 0.92)
LYPD3	0.67 (0.54 - 0.79)	0.22 (0.04 - 0.43)	0.24 (0.06 - 0.39)	0.89 (0.87 - 0.92)
CA9	0.73 (0.64 - 0.82)	0.17 (0.04 - 0.35)	0.20 (0.06 - 0.33)	0.88 (0.87 - 0.91)
FCRLB	0.69 (0.59 - 0.79)	0.26 (0.04 - 0.43)	0.27 (0.06 - 0.39)	0.89 (0.87 - 0.92)
TCL1A	0.58 (0.45 - 0.70)	0.17 (0.04 - 0.39)	0.20 (0.06 - 0.36)	0.88 (0.87 - 0.91)
MDK	0.70 (0.59 - 0.81)	0.35 (0.17 - 0.57)	0.33 (0.20 - 0.45)	0.91 (0.88 - 0.94)
CDKN1A	0.62 (0.49 - 0.74)	0.13 (0.00 - 0.43)	0.16 (0.00 - 0.39)	0.88 (0.86 - 0.92)
FURIN	0.64 (0.51 - 0.77)	0.22 (0.04 - 0.48)	0.24 (0.06 - 0.41)	0.89 (0.87 - 0.92)
TNFSF13	0.64 (0.52 - 0.76)	0.22 (0.04 - 0.43)	0.24 (0.06 - 0.39)	0.89 (0.87 - 0.92)
GAL	0.61 (0.47 - 0.72)	0.17 (0.04 - 0.39)	0.20 (0.06 - 0.36)	0.88 (0.87 - 0.91)
TNFSF10	0.66 (0.54 - 0.77)	0.22 (0.04 - 0.39)	0.24 (0.06 - 0.36)	0.89 (0.87 - 0.91)
CPE	0.64 (0.50 - 0.76)	0.22 (0.04 - 0.43)	0.24 (0.06 - 0.39)	0.89 (0.87 - 0.92)
WFDC2	0.75 (0.62 - 0.86)	0.30 (0.09 - 0.61)	0.31 (0.11 - 0.47)	0.90 (0.87 - 0.94)
PPY	0.62 (0.51 - 0.73)	0.17 (0.04 - 0.35)	0.20 (0.06 - 0.33)	0.88 (0.87 - 0.91)
METAP2	0.62 (0.47 - 0.75)	0.26 (0.09 - 0.48)	0.27 (0.11 - 0.41)	0.89 (0.87 - 0.92)
XPNPEP2	0.57 (0.45 - 0.69)	0.09 (0.00 - 0.30)	0.11 (0.00 - 0.31)	0.87 (0.86 - 0.90)
NECTIN4	0.62 (0.49 - 0.75)	0.26 (0.04 - 0.48)	0.27 (0.06 - 0.41)	0.89 (0.87 - 0.92)
Creatinine	0.44 (0.29 - 0.58)	0.09 (0.00 - 0.27)	0.12 (0.00 - 0.29)	0.87 (0.86 - 0.89)
KLK8	0.65 (0.52 - 0.78)	0.26 (0.04 - 0.48)	0.27 (0.06 - 0.41)	0.89 (0.87 - 0.92)
CD207	0.51 (0.38 - 0.64)	0.04 (0.00 - 0.17)	0.06 (0.00 - 0.20)	0.87 (0.86 - 0.88)
MIA	0.51 (0.40 - 0.63)	0.04 (0.00 - 0.17)	0.06 (0.00 - 0.20)	0.87 (0.86 - 0.88)
GPNMB	0.70 (0.58 - 0.81)	0.30 (0.09 - 0.52)	0.31 (0.11 - 0.43)	0.90 (0.87 - 0.93)
ERBB2	0.47 (0.34 - 0.61)	0.13 (0.00 - 0.30)	0.16 (0.00 - 0.31)	0.88 (0.86 - 0.90)
DLL1	0.65 (0.52 - 0.78)	0.26 (0.04 - 0.52)	0.27 (0.06 - 0.43)	0.89 (0.87 - 0.93)
TNFRSF19	0.52 (0.39 - 0.65)	0.13 (0.00 - 0.30)	0.16 (0.00 - 0.31)	0.88 (0.86 - 0.90)
AR	0.70 (0.57 - 0.81)	0.22 (0.04 - 0.52)	0.24 (0.06 - 0.43)	0.89 (0.87 - 0.93)
NT5E	0.68 (0.55 - 0.80)	0.22 (0.04 - 0.48)	0.24 (0.06 - 0.41)	0.89 (0.87 - 0.92)
THBS2	0.73 (0.61 - 0.84)	0.43 (0.22 - 0.65)	0.39 (0.24 - 0.49)	0.92 (0.89 - 0.95)
ADAM8	0.50 (0.38 - 0.62)	0.09 (0.00 - 0.26)	0.11 (0.00 - 0.27)	0.87 (0.86 - 0.89)
GZMB	0.60 (0.47 - 0.73)	0.22 (0.09 - 0.39)	0.24 (0.11 - 0.36)	0.89 (0.87 - 0.91)
IGF1R	0.51 (0.38 - 0.64)	0.09 (0.00 - 0.22)	0.11 (0.00 - 0.24)	0.87 (0.86 - 0.89)
PKM	0.61 (0.46 - 0.75)	0.23 (0.05 - 0.45)	0.25 (0.06 - 0.40)	0.89 (0.86 - 0.92)
KLK14	0.51 (0.37 - 0.65)	0.22 (0.04 - 0.39)	0.24 (0.06 - 0.36)	0.89 (0.87 - 0.91)
ERBB3	0.61 (0.50 - 0.72)	0.13 (0.00 - 0.35)	0.16 (0.00 - 0.33)	0.88 (0.86 - 0.91)
CRNN	0.68 (0.57 - 0.78)	0.17 (0.04 - 0.35)	0.20 (0.06 - 0.33)	0.88 (0.87 - 0.91)
FOLR3	0.54 (0.44 - 0.65)	0.09 (0.00 - 0.22)	0.11 (0.00 - 0.24)	0.87 (0.86 - 0.89)
CXCL13	0.44 (0.31 - 0.58)	0.00 (0.00 - 0.13)	0.00 (0.00 - 0.16)	0.86 (0.86 - 0.88)
SEZ6L	0.61 (0.48 - 0.73)	0.17 (0.04 - 0.35)	0.20 (0.06 - 0.33)	0.88 (0.87 - 0.91)

KLK13	0.63 (0.51 - 0.74)	0.09 (0.00 - 0.26)	0.11 (0.00 - 0.27)	0.07 (0.06 0.00)
S100A11	0.58 (0.45 - 0.70)	0.17 (0.00 - 0.35)	0.20 (0.00 - 0.33)	0.87 (0.86 - 0.89) 0.88 (0.86 - 0.91)
ITGB5	0.50 (0.36 - 0.62)	0.00 (0.00 - 0.13)	0.00 (0.00 - 0.16)	0.86 (0.86 - 0.88)
	, ,	,	, ,	, ,
IL6	0.69 (0.58 - 0.80)	0.13 (0.00 - 0.39)	0.16 (0.00 - 0.36)	0.88 (0.86 - 0.91)
MICA/B	0.58 (0.45 - 0.69)	0.13 (0.00 - 0.30)	0.16 (0.00 - 0.31)	0.88 (0.86 - 0.90)
CXCL17	0.52 (0.41 - 0.64)	0.04 (0.00 - 0.17)	0.06 (0.00 - 0.20)	0.87 (0.86 - 0.88)
CD70	0.49 (0.35 - 0.61)	0.09 (0.00 - 0.26)	0.11 (0.00 - 0.27)	0.87 (0.86 - 0.89)
CD160	0.51 (0.36 - 0.65)	0.09 (0.00 - 0.26)	0.11 (0.00 - 0.27)	0.87 (0.86 - 0.89)
TLR3	0.68 (0.54 - 0.80)	0.43 (0.17 - 0.65)	0.39 (0.20 - 0.49)	0.92 (0.88 - 0.95)
VIM	0.49 (0.36 - 0.62)	0.13 (0.00 - 0.26)	0.16 (0.00 - 0.27)	0.88 (0.86 - 0.89)
IFNGR1	0.54 (0.40 - 0.69)	0.13 (0.00 - 0.35)	0.16 (0.00 - 0.33)	0.88 (0.86 - 0.91)
FGFBP1	0.62 (0.49 - 0.75)	0.22 (0.09 - 0.43)	0.24 (0.11 - 0.39)	0.89 (0.87 - 0.92)
LY9	0.49 (0.36 - 0.62)	0.04 (0.00 - 0.17)	0.06 (0.00 - 0.20)	0.87 (0.86 - 0.88)
FOLR1	0.51 (0.37 - 0.63)	0.09 (0.00 - 0.22)	0.11 (0.00 - 0.24)	0.87 (0.86 - 0.89)
MSLN	0.67 (0.56 - 0.79)	0.35 (0.00 - 0.52)	0.33 (0.00 - 0.43)	0.91 (0.86 - 0.93)
PODXL	0.47 (0.34 - 0.61)	0.09 (0.00 - 0.26)	0.11 (0.00 - 0.27)	0.87 (0.86 - 0.89)
GZMH	0.47 (0.33 - 0.60)	0.13 (0.00 - 0.30)	0.16 (0.00 - 0.31)	0.88 (0.86 - 0.90)
S100A4	0.54 (0.41 - 0.66)	0.13 (0.00 - 0.26)	0.16 (0.00 - 0.27)	0.88 (0.86 - 0.89)
ERBB4	0.48 (0.34 - 0.60)	0.09 (0.00 - 0.22)	0.11 (0.00 - 0.24)	0.87 (0.86 - 0.89)
TGFBR2	0.49 (0.36 - 0.63)	0.00 (0.00 - 0.17)	0.00 (0.00 - 0.20)	0.86 (0.86 - 0.88)
SMAD5	0.62 (0.51 - 0.73)	0.04 (0.00 - 0.22)	0.06 (0.00 - 0.24)	0.87 (0.86 - 0.89)
VEGFA	0.53 (0.40 - 0.65)	0.09 (0.00 - 0.26)	0.11 (0.00 - 0.27)	0.87 (0.86 - 0.89)
CD48	0.51 (0.39 - 0.64)	0.04 (0.00 - 0.22)	0.06 (0.00 - 0.24)	0.87 (0.86 - 0.89)
RSP03	0.48 (0.35 - 0.61)	0.09 (0.00 - 0.26)	0.11 (0.00 - 0.27)	0.87 (0.86 - 0.89)
CCN4	0.62 (0.49 - 0.74)	0.22 (0.04 - 0.43)	0.24 (0.06 - 0.39)	0.89 (0.87 - 0.92)
IL6ST	0.68 (0.52 - 0.81)	0.39 (0.22 - 0.61)	0.36 (0.24 - 0.47)	0.91 (0.89 - 0.94)
LYN	0.52 (0.39 - 0.65)	0.22 (0.04 - 0.39)	0.24 (0.06 - 0.36)	0.89 (0.87 - 0.91)
SCAMP3	0.49 (0.38 - 0.61)	0.00 (0.00 - 0.17)	0.00 (0.00 - 0.20)	0.86 (0.86 - 0.88)
CCN1	0.50 (0.40 - 0.60)	0.00 (0.00 - 0.04)	0.00 (0.00 - 0.06)	0.86 (0.86 - 0.87)
SPARC	0.52 (0.40 - 0.64)	0.04 (0.00 - 0.26)	0.06 (0.00 - 0.27)	0.87 (0.86 - 0.89)
TNFRSF4	0.64 (0.51 - 0.76)	0.26 (0.00 - 0.48)	0.27 (0.00 - 0.41)	0.89 (0.86 - 0.92)
ABL1	0.51 (0.39 - 0.63)	0.00 (0.00 - 0.13)	0.00 (0.00 - 0.16)	0.86 (0.86 - 0.88)
CEACAM1	0.54 (0.41 - 0.66)	0.17 (0.04 - 0.35)	0.20 (0.06 - 0.33)	0.88 (0.87 - 0.91)
FADD	0.55 (0.44 - 0.66)	0.00 (0.00 - 0.13)	0.00 (0.00 - 0.16)	0.86 (0.86 - 0.88)
ADAMTS15	0.52 (0.39 - 0.65)	0.13 (0.00 - 0.26)	0.16 (0.00 - 0.27)	0.88 (0.86 - 0.89)
CD27	0.61 (0.47 - 0.74)	0.26 (0.09 - 0.52)	0.27 (0.11 - 0.43)	0.89 (0.87 - 0.93)
HGF	0.51 (0.38 - 0.64)	0.13 (0.00 - 0.30)	0.16 (0.00 - 0.31)	0.88 (0.86 - 0.90)
KLK11	0.59 (0.46 - 0.70)	0.13 (0.00 - 0.30)	0.16 (0.00 - 0.31)	0.88 (0.86 - 0.90)
ANXA1	0.50 (0.37 - 0.62)	0.09 (0.00 - 0.22)	0.11 (0.00 - 0.24)	0.87 (0.86 - 0.89)
FLT4	0.50 (0.36 - 0.62)	0.13 (0.00 - 0.26)	0.16 (0.00 - 0.27)	0.88 (0.86 - 0.89)
GPC1	0.57 (0.42 - 0.71)	0.26 (0.09 - 0.48)	0.27 (0.11 - 0.41)	0.89 (0.87 - 0.92)

Supplementary Table 5 Stack logistic regression model coefficient estimates and respective 95% confidence interval (CI) limits and p values. See statistical analysis sub-section in Methods for the detailed description of the stacking procedure. This model was developed in the discovery set.

	Coefficient Estimate	CI 2.5%	CI 97.5%	p value
Intercept	-1.47	-2.34	-0.73	0.00033
Diagnosis				
Healthy	2.50	1.75	3.45	5.41×10 <sup>-9</sup>
Chronic Pancreatitis	2.30	1.57	3.20	2.26×10 <sup>-8</sup>
IgG4 Disease	2.08	1.26	3.07	4.98×10 <sup>-6</sup>
Irritable Bowel Syndrome	1.92	1.08	2.86	1.61×10 <sup>-5</sup>
Other Biliary Duct Disease	2.29	1.15	3.56	0.00016
Sphincter of Oddi Dysfunction	1.64	0.73	2.65	0.00063
No Relevant Diagnosis	-1.73	-3.23	-0.39	0.015
Other Cancer	0.77	0.076	1.51	0.032
Pancreatic Cyst	-1.52	-3.02	-0.17	0.035
Gastritis/Reflux Disease	0.53	-0.44	1.53	0.28
Familial Pancreatic Cancer	0.49	-0.41	1.41	0.29
Acute Pancreatitis	0.34	-0.29	1.027	0.31
Liver Disease	0.38	-0.35	1.14	0.31
Isolated LFTs Derangement	-0.63	-2.03	0.60	0.34
Non-Specific Abdominal Pain	0.301	-0.47	1.05	0.43
Gallstone Disease	0.18	-0.67	1.07	0.68

Supplementary Table 6 Discovery set data and univariate association with PDAC status. Odds ratios (OR), 95% confidence intervals (CI) and p values were calculated according to a logistic regression model with a bias reduction method (see statistical section in Methods).

#### 

Variable	Cases C		Co	ntrols	OR		p value			
Number of samples		24		,	333	-		-		
Mean age at sample dra	w (yr) (range)	70.79 (43.00-9	91.00)	58.39(19	9.00-89.00)	1.07 (1.03	- 1.11)	4.68e	-05	
Mean BMI (kg/m2) (rang	je)	25.46 (19.81-4	11.35)	25.41 (1	5.22-42.19)	1.01 (0.89	-1.12)	0.8	0.87	
Gender										
	Male	18			121	4.98 (2.08 -	- 13.50)	0.000	123	
Female		6	212				0.00023			
Diabetes										
	yes	5			52					
no		281		19		1.51 (0.51 – 3.84)		0.43		
Ethnicity										
	Caucasian	11		,	189					
	Unknown	9			99					
Asian		3		15		1.17 (0.70	- 2.02)	0.5	6	
Other		1		13						
	Afro/Caribbean	0			17					

 Supplementary Table 7 Validation set data and univariate association with PDAC status. Odds ratios (OR), 95% confidence intervals (CI) and p values were calculated according to a logistic regression model with a bias reduction method (see statistical section in Methods).

Variable		Case	es	C	Controls	OR	1	p value
Number of Samples		23			159		-	
Mean age at sample draw (yr)	(range)	68.61 (53.0	0 - 83.00)	57.94 (	21.00 - 93.00)	1.06 (1.02	2 -1.04)	0.00071
Mean BMI (kg/m2) (range)		24.18 (12.04	4 - 31.62)	25.64 (	17.60 - 38.30)	0.90 (0.78	3-1.01)	0.080
Gender								
	Male	14			58	2.65 (1.11	- 6.58)	0.028
	Female	9			101	-		
Diabetes								
	yes	5			52			
	no	281		19		1.57 (0.51	- 4.23)	0.41
Ethnicity								
С	aucasian	10			102			
ı	Jnknown	12			32			
Asian		3		15		2.66 (1.42	<b>–</b> 5.17)	0.0020
	Other	1		5				
Afro/C	aribbean	0			5			

 Supplementary Table 8 Type and number of subjects with other cancers in the ADEPTS cohort. See also Figure 1.

Other Cancer	Number of subjects
Possible gallbladder cancer	1
Low grade dysplasia on ampulla of Vater (Incidental finding)	1
Hilar cholangiocarcinoma, treated Nov 2017	1
Low anal moderately differentiated adenocarcinoma	1
Cholangiocarcinoma, primary sclerosing cholangitis	1
PNET (insulinoma)	1
Bowel cancer in 2011	1
Prostate cancer	1

**Supplementary Table 9 Values corresponding to Figure 4.** Only ADEPTS samples were considered for this association study. Given that symptoms were not considered in the training of the classifiers, we concatenate ADEPTS samples in the discovery and validation sets to verify the associations of symptoms and PDAC. A univariate logistic regression model with bias correction was used for each symptom to test the association with PDAC.

	Number of subjects						
	Yes No		)	(()	_		
Symptoms	Control	Case	Case Control Case		OR (95% CI)	p value	
Jaundice	18	22	401	23	20.78 (9.98 - 44.35)	3.22×10 <sup>-15</sup>	
Weight Loss	39	17	380	28	5.91 (2.96 - 11.62)	1.44×10 <sup>-06</sup>	
Asymptomatic	96	3	323	42	0.28 (0.07- 0.74)	0.0077	
Reflux	38	0	381	45	0.11 (0.00 - 0.79)	0.022	
Bloating	31	0	388	45	0.14 (0.00 - 0.99)	0.048	
Dyspepsia	30	0	389	45	0.14 (0.00 - 1.03)	0.054	
Abdominal Pain	198	16	221	29	0.62 (0.33 - 1.16)	0.14	
Nausea	20	0	399	45	0.21 (0.00 - 1.60)	0.17	
Vomiting	19	4	400	41	2.23 (0.67 - 6.03)	0.17	
Asymptomatic LFT Derangement	52	8	367	37	1.59 (0.67 - 3.39)	0.28	
Anaemia	24	1	395	44	0.54 (0.06 - 2.18)	0.44	
Back Pain	1	0	418	45	3.07 (0.02 - 58.34)	0.54	
Heartburn	9	0	410	45	0.47 (0.00 - 3.85)	0.57	
Change In Bowel Habit	58	7	361	38	1.20 (0.49 - 2.62)	0.67	
Rectal Bleeding	10	1	409	44	1.31 (0.14 - 5.80)	0.76	
Dysphagia	16	1	403	44	0.82 (0.09 - 3.42)	0.82	

Supplementary Table 10 Performance model rank summary for selected models in symptomatic patients. The probability values used to calculate the performance metrics were generated with each model developed in the training set and reported in the main text. Probability values for symptomatic patients belonging to the training set and validation set were concatenated to generate the ROC curves. Only ADEPTS samples had symptoms information. A. L. Derang.: Asymptomatic LFT Derangement. B. Pain: Back Pain. C. B. Habit: Change in Bowel Habit. W. Loss: Weight Loss. Here, only the ranks of the performances are provided. For the respective performance values see Table 2 in the main text.

Symptom (Yes)								
Models	Metric	A.L.Derang.	A.Pain	A.B. Habit	W. Loss	Jaundice	Geometric mean rank	Mean across all metrics
CA19-9	ROC	3	3	3	3	3	3.00	
	Sens90	3	3	2	3	3	2.77	2.83
	PPV90	3	3	2	3	3	2.77	
	NPV90	3	3	2	3	3	2.77	
Index signature	ROC	1	1	1	1	1	1.00	
	Sens90	2	1	1	1	2	1.32	1.16
	PPV90	2	1	1	1	1	1.15	
	NPV90	1	1	1	1	2	1.15	
Reduced signature	ROC	2	2	2	2	2	2.00	1.79
	Sens90	1	2	3	2	1	1.64	
	PPV90	1	2	3	2	2	1.89	
	NPV90	1	2	3	2	1	1.64	

Supplementary Table 11 Pairwise area under receiver operating characteristic curve comparison p-values for the selected models in Table 2 (main text). Only ADEPTS samples had symptoms information. A. L. Derang.: Asymptomatic LFT Derangement. B. Pain: Back Pain. C. B. Habit: Change in Bowel Habit. W. Loss: Weight Loss. For the respective performance values see Table 2 in the main text. Models in rows for each symptom are compared with those in the columns for the same symptom. 10000 bootstraps were constructed to test the significance of the difference in performance being lower.

Symptom (Yes)		Reduced signature	Index signature
A.L.Derang.	CA19-9	3.89×10 <sup>-07</sup>	7.70×10 <sup>-26</sup>
	Reduced signature	-	0.25
A. Pain	CA19-9	2.19×10 <sup>-15</sup>	2.83×10 <sup>-93</sup>
	Reduced signature	-	1.08×10 <sup>-06</sup>
A. B. Habit	CA19-9	0.0018	1.48×10 <sup>-28</sup>
	Reduced signature	-	0.020
W.Loss	CA19-9	2.04×10 <sup>-09</sup>	1.38×10 <sup>-14</sup>
	Reduced signature		0.018
Jaundice	CA19-9	0.013	3.34×10 <sup>-07</sup>
	Reduced signature	-	0.069

## 1230

#### 1231

#### 1232

#### 1233

## 1234

## 1235

# 12361237

#### References

- 1238
- 1239 1. Kamisawa T, Wood LD, Itoi T, Takaori K. Pancreatic cancer. The Lancet. 2016;388:73-1240 85.
- 1241 2. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global
- 1242 Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36
- 1243 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians. 2021;71:209-49.
- 1244 3. Carioli G, Malvezzi M, Bertuccio P, Boffetta P, Levi F, Vecchia CL, et al. European
- cancer mortality predictions for the year 2021 with focus on pancreatic and female lung cancer. Annals of Oncology. 2021;32:478-87.
- 1247 4. Dalmartello M, La Vecchia C, Bertuccio P, Boffetta P, Levi F, Negri E, et al. European
- cancer mortality predictions for the year 2022 with focus on ovarian cancer. Ann Oncol. 2022;33(3):330-9.
- 1250 5. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM.
- 1251 Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver,
- and Pancreas Cancers in the United States. Cancer Research. 2014;74:2913-21.
- 1253 6. Huang J, Lok V, Ngai CH, Zhang L, Yuan J, Lao XQ, et al. Worldwide Burden of, Risk
- 1254 Factors for, and Trends in Pancreatic Cancer. Gastroenterology. 2021;160:744-54.

- 1255 7. Marchegiani G, Andrianello S, Malleo G, De Gregorio L, Scarpa A, Mino-Kenudson M,
- et al. Does Size Matter in Pancreatic Cancer?: Reappraisal of Tumour Dimension as a
- 1257 Predictor of Outcome Beyond the TNM. Annals of Surgery. 2017;266(1).
- 1258 8. Zerboni G, Signoretti M, Crippa S, Falconi M, Arcidiacono PG, Capurso G. Systematic
- review and meta-analysis: Prevalence of incidentally detected pancreatic cystic lesions in
- asymptomatic individuals. Pancreatology. 2019;19:2-9.
- 1261 9. Pereira SP, Oldfield L, Ney A, Hart PA, Keane MG, Pandol SJ, et al. Early detection of
- 1262 pancreatic cancer. The Lancet Gastroenterology and Hepatology. 2020.
- 1263 10. Aslanian HR, Lee JH, Canto MI. AGA Clinical Practice Update on Pancreas Cancer
- 1264 Screening in High-Risk Individuals: Expert Review. Gastroenterology. 2020;159:358-62.
- 1265 11. Owens DK, Davidson KW, Krist AH, Barry MJ, Cabana M, Caughey AB, et al. Screening
- 1266 for Pancreatic Cancer. JAMA. 2019;322:438-.
- 1267 12. Chhoda A, Vodusek Z, Wattamwar K, Mukherjee E, Gunderson C, Grimshaw A, et al.
- 1268 Late-Stage Pancreatic Cancer Detected During High-Risk Individual Surveillance: A
- 1269 Systematic Review and Meta-Analysis. Gastroenterology. 2022;162:786-98.
- 1270 13. European evidence-based guidelines on pancreatic cystic neoplasms. Gut.
- 1271 2018;67:789-804.
- 1272 14. Walter FM, Mills K, Mendonça SC, Abel GA, Basu B, Carroll N, et al. Symptoms and
- patient factors associated with diagnostic intervals for pancreatic cancer (SYMPTOM
- pancreatic study): a prospective cohort study. The Lancet Gastroenterology & Hepatology.
- 1275 2016;1:298-306.
- 1276 15. Lukacs G, Kovacs A, Csanadi M, Moizs M, Repa I, Kalo Z, et al. Benefits Of Timely Care
- 1277 In Pancreatic Cancer: A Systematic Review To Navigate Through The Contradictory Evidence.
- 1278 Cancer Manag Res. 2019;11:9849-61.
- 1279 16. Yu J, Blackford AL, Dal Molin M, Wolfgang CL, Goggins M. Time to progression of
- pancreatic ductal adenocarcinoma from low-to-high tumour stages. Gut. 2015;64(11):1783-
- 1281 9.
- 1282 17. Ahn SJ, Choi SJ, Kim HS. Time to Progression of Pancreatic Cancer: Evaluation with
- Multi-Detector Computed Tomography. J Gastrointest Cancer. 2017;48(2):164-9.
- 1284 18. Lyratzopoulos G, Wardle J, Rubin G. Rethinking diagnostic delay in cancer: how
- difficult is the diagnosis? BMJ. 2014;349:g7400.
- 1286 19. Escorza-Calzada S, Rosas-Camargo V, Melchor-Ruan J, Meneses-Medina M, Cedro-
- 1287 Tanda A, Huitzil-Melendez F. P-319 Delay in pancreatic cancer diagnosis and treatment: Call
- to action. Annals of Oncology. 2023;34:S127.
- 1289 20. Keane MG, Horsfall L, Rait G, Pereira SP. A case-control study comparing the
- incidence of early symptoms in pancreatic and biliary tract cancer. BMJ open.
- 1291 2014;4:e005720-e.
- 1292 21. Liao W, Clift AK, Patone M, Coupland C, González-Izquierdo A, Pereira SP, et al.
- 1293 Identifying symptoms associated with diagnosis of pancreatic exocrine and neuroendocrine
- neoplasms: a nested case-control study of the UK primary care population. British Journal of
- 1295 General Practice. 2021;71:e836-e45.
- 1296 22. Schmidt-Hansen M, Berendse S, Hamilton W. Symptoms of Pancreatic Cancer in
- 1297 Primary Care. Pancreas. 2016;45:814-8.
- 1298 23. Mizrahi JD, Surana R, Valle JW, Shroff RT. Pancreatic cancer. The Lancet.
- 1299 2020;395:2008-20.
- 1300 24. [Available from: https://www.nice.org.uk.

- 1301 25. Hippisley-Cox J, Coupland C. Development and validation of risk prediction
- algorithms to estimate future risk of common cancers in men and women: prospective
- 1303 cohort study. BMJ Open. 2015;5:e007825-e.
- 1304 26. Hamilton W. The CAPER studies: five case-control studies aimed at identifying and
- 1305 quantifying the risk of cancer in symptomatic primary care patients. British Journal of
- 1306 Cancer. 2009;101:S80-S6.
- 1307 27. Usher-Smith J, Emery J, Hamilton W, Griffin SJ, Walter FM. Risk prediction tools for
- cancer in primary care. British Journal of Cancer. 2015;113:1645-50.
- 1309 28. Humphris JL, Chang DK, Johns AL, Scarlett CJ, Pajic M, Jones MD, et al. The prognostic
- and predictive value of serum CA19.9 in pancreatic cancer. Annals of Oncology.
- 1311 2012;23:1713-22.
- 1312 29. Luo G, Jin K, Deng S, Cheng H, Fan Z, Gong Y, et al. Roles of CA19-9 in pancreatic
- cancer: Biomarker, predictor and promoter. Biochimica et Biophysica Acta (BBA) Reviews
- 1314 on Cancer. 2021;1875(2):188409.
- 1315 30. Ballehaninna UK, Chamberlain RS. The clinical utility of serum CA 19-9 in the
- diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based
- 1317 appraisal. J Gastrointest Oncol. 2012;3(2):105-19.
- 1318 31. Kim Y, Yeo I, Huh I, Kim J, Han D, Jang JY, et al. Development and Multiple Validation
- of the Protein Multi-marker Panel for Diagnosis of Pancreatic Cancer. Clin Cancer Res.
- 1320 2021;27(8):2236-45.
- 1321 32. Potjer TP. Pancreatic cancer surveillance and its ongoing challenges: is it time to
- refine our eligibility criteria? Gut. 2022;71:1047-9.
- 1323 33. Pereira S, Hippisley-Cox J, Timms J, Hsuan J, Fusai K, Williams N, et al. ADEPTS
- 1324 (Accelerated Diagnosis of neuroEndocrine and Pancreatic TumourS) and EDRA (Early
- Diagnosis Research Alliance). Pancreatology. 2020;20(8):e14.
- 1326 34. Price S, Spencer A, Medina-Lara A, Hamilton W. Availability and use of cancer
- decision-support tools: a cross-sectional survey of UK primary care. Br J Gen Pract.
- 1328 2019;69(684):e437-e43.
- 1329 35. Menon U, Gentry-Maharaj A, Burnell M, Singh N, Ryan A, Karpinskyj C, et al. Ovarian
- cancer population screening and mortality after long-term follow-up in the UK Collaborative
- 1331 Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet.
- 1332 2021;397(10290):2182-93.
- 1333 36. Nené NR, Ney A, Nazarenko T, Blyuss O, Johnston HE, Whitwell HJ, et al. Serum
- biomarker-based early detection of pancreatic ductal adenocarcinomas with ensemble
- learning. Communications Medicine. 2023;3:10-.
- 1336 37. Menon U, Gentry-Maharaj A, Hallett R, Ryan A, Burnell M, Sharma A, et al. Sensitivity
- and specificity of multimodal and ultrasound screening for ovarian cancer, and stage
- distribution of detected cancers: results of the prevalence screen of the UK Collaborative
- 1339 Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol. 2009;10(4):327-40.
- 1340 38. Menon U, Gentry-Maharaj A, Ryan A, Sharma A, Burnell M, Hallett R, et al.
- Recruitment to multicentre trials--lessons from UKCTOCS: descriptive study. Bmj.
- 1342 2008;337:a2079.
- 1343 39. O'Brien DP, Sandanayake NS, Jenkinson C, Gentry-Maharaj A, Apostolidou S,
- Fourkala EO, et al. Serum CA19-9 is significantly up-regulated up to 2 years prior to diagnosis
- with pancreatic cancer: implications for early disease detection. Clin Cancer Res.
- 1346 2015;21(3):622-31.

- 1347 40. Data normalization and standardization [Available from:
- 1348 https://www.olink.com/content/uploads/2021/09/olink-data-normalization-white-paper-
- 1349 v2.0.pdf.
- 1350 41. Nené NR, Ney A, Nazarenko T, Blyuss O, Johnston HE, Whitwell HJ, et al. Early
- detection of pancreatic ductal adenocarcinomas with an ensemble learning model based on
- 1352 a panel of protein serum biomarkers. medRxiv. 2021:2021.12.02.21267187.
- 1353 42. Caruana R, Niculescu-Mizil A, Crew G, Ksikes A. Ensemble selection from libraries of
- models. Proceedings of the twenty-first international conference on Machine learning;
- 1355 Banff, Alberta, Canada: Association for Computing Machinery; 2004. p. 18.
- 1356 43. Whalen S, Pandey G, editors. A Comparative Analysis of Ensemble Classifiers: Case
- 1357 Studies in Genomics. 2013 IEEE 13th International Conference on Data Mining; 2013 7-10
- 1358 Dec. 2013.
- 1359 44. Ambroise C, McLachlan GJ. Selection bias in gene extraction on the basis of
- microarray gene-expression data. Proc Natl Acad Sci U S A. 2002;99(10):6562-6.
- 1361 45. Whalen S, Schreiber J, Noble WS, Pollard KS. Navigating the pitfalls of applying
- machine learning in genomics. Nat Rev Genet. 2022;23(3):169-81.
- 1363 46. Teschendorff AE. Avoiding common pitfalls in machine learning omic data science.
- 1364 Nat Mater. 2019;18(5):422-7.
- 1365 47. Julia H-C, Carol C. Development and validation of risk prediction algorithms to
- estimate future risk of common cancers in men and women: prospective cohort study. BMJ
- 1367 Open. 2015;5(3):e007825.
- 1368 48. Scholbeck CA, Molnar C, Heumann C, Bischl B, Casalicchio G, editors. Sampling,
- 1369 Intervention, Prediction, Aggregation: A Generalized Framework for Model-Agnostic
- 1370 Interpretations. Machine Learning and Knowledge Discovery in Databases; 2020 2020//;
- 1371 Cham: Springer International Publishing.
- 1372 49. James AD, Richardson DA, Oh IW, Sritangos P, Attard T, Barrett L, et al. Cutting off
- the fuel supply to calcium pumps in pancreatic cancer cells: role of pyruvate kinase-M2
- 1374 (PKM2). Br J Cancer. 2020;122(2):266-78.
- 1375 50. Matull WR, Andreola F, Loh A, Adiguzel Z, Deheragoda M, Qureshi U, et al. MUC4
- and MUC5AC are highly specific tumour-associated mucins in biliary tract cancer. Br J
- 1377 Cancer. 2008;98(10):1675-81.
- 1378 51. Cuenco J, Wehnert N, Blyuss O, Kazarian A, Whitwell HJ, Menon U, et al.
- 1379 Identification of a serum biomarker panel for the differential diagnosis of
- cholangiocarcinoma and primary sclerosing cholangitis. Oncotarget. 2018;9(25):17430-42.
- 1381 52. Stecher C, Battin C, Leitner J, Zettl M, Grabmeier-Pfistershammer K, Höller C, et al.
- 1382 PD-1 Blockade Promotes Emerging Checkpoint Inhibitors in Enhancing T Cell Responses to
- 1383 Allogeneic Dendritic Cells. Frontiers in Immunology. 2017;8.
- 1384 53. Riquelme E, Zhang Y, Zhang L, Montiel M, Zoltan M, Dong W, et al. Tumor
- 1385 Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes. Cell.
- 1386 2019;178(4):795-806 e12.
- 1387 54. Peng H, James CA, Cullinan DR, Hogg GD, Mudd JL, Zuo C, et al. Neoadjuvant
- 1388 FOLFIRINOX Therapy Is Associated with Increased Effector T Cells and Reduced Suppressor
- 1389 Cells in Patients with Pancreatic Cancer. Clinical Cancer Research. 2021;27(24):6761-71.
- 1390 55. Wang C, Li X, Zhang L, Chen Y, Dong R, Zhang J, et al. miR-194-5p down-regulates
- tumor cell PD-L1 expression and promotes anti-tumor immunity in pancreatic cancer. Int
- 1392 Immunopharmacol. 2021;97:107822.
- 1393 56. QCancer®-2018 risk calculator for men: http://qcancer.org/male [

- 1394 57. QCancer®-2018 risk calculator for women: <a href="http://qcancer.org/female">http://qcancer.org/female</a> [
- 1395 58. Kane LE, Mellotte GS, Mylod E, O'Brien RM, O'Connell F, Buckley CE, et al. Diagnostic
- 1396 Accuracy of Blood-based Biomarkers for Pancreatic Cancer: A Systematic Review and Meta-
- analysis. Cancer Res Commun. 2022;2(10):1229-43.
- 1398 59. Sturm N, Ettrich TJ, Perkhofer L. The Impact of Biomarkers in Pancreatic Ductal
- 1399 Adenocarcinoma on Diagnosis, Surveillance and Therapy. Cancers. 2022;14:217-.
- 1400 60. Azizian A, Ruhlmann F, Krause T, Bernhardt M, Jo P, Konig A, et al. CA19-9 for
- detecting recurrence of pancreatic cancer. Sci Rep. 2020;10(1):1332.
- 1402 61. Sagi O, Rokach L. Ensemble learning: A survey. WIREs Data Mining and Knowledge
- 1403 Discovery. 2018;8(4):e1249.
- 1404 62. Benjamin JL, Maruan A-S, Amir A, Jennifer W, Sami L, Eric PX. Discriminative
- Subtyping of Lung Cancers from Histopathology Images via Contextual Deep Learning.
- 1406 medRxiv. 2022:2020.06.25.20140053.
- 1407 63. Placido D, Yuan B, Hjaltelin JX, Zheng C, Haue AD, Chmura PJ, et al. A deep learning
- algorithm to predict risk of pancreatic cancer from disease trajectories. Nat Med.
- 1409 2023;29(5):1113-22.

- 1410 64. Whitwell HJ, Worthington J, Blyuss O, Gentry-Maharaj A, Ryan A, Gunu R, et al.
- 1411 Improved early detection of ovarian cancer using longitudinal multimarker models. British
- 1412 Journal of Cancer. 2020;122(6):847-56.